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Cellular invasion represents a critical early step in the metastatic cascade, and
many proteins have been identified as part of an “invasive signature.” The non‐receptor
tyrosine kinase Src is commonly upregulated in breast cancers, often in conjunction with
overexpression of EGFR. Signaling from this pathway stimulates cell proliferation,
migration, and invasion and frequently involves proteins that regulate the cytoskeleton.
My data demonstrates that inhibition of Src, using the small‐molecule inhibitor dasatinib,
impairs cellular migration and invasion. Furthermore, Src inhibition sensitizes the cells to
the effects of the chemotherapeutic doxorubicin resulting in dramatic, synergistic
inhibition of proliferation with combination treatments. The Src‐targeted protein CIP4
(Cdc42‐interacting protein 4) associates with curved plasma membranes to scaffold
complexes of Cdc42 and N‐WASp. In these experiments, I show that CIP4 overexpression
correlates with triple‐negative biomarker status, cellular migration, and invasion of
(breast cancer cells. Inhibition of CIP4 expression significantly decreases migration and
invasion. Furthermore, I demonstrate the novel finding that CIP4 localizes to invadopodia,
which are finger‐like projections of the actin cytoskeleton that are associated with matrix
degradation and cellular invasion. Depletion of CIP4 in invasive cells impairs the
formation of invadopodia and the degradation of gelatin. Therefore, CIP4 is a critical
component of the invasive phenotype acquired by human breast cancer cells. In this body
of work, I propose a model in which CIP4 promotes actin polymerization by stabilizing the
active conformation of N‐WASp. CIP4 and N‐WASp are both phosphorylated by Src,
implicating this pathway in Src‐dependent cytoskeletal rearragement. This represents a
novel role for F‐BAR proteins in migration and invasion.

v

TABLE OF CONTENTS

Page

APPROVAL PAGE

i

TITLE PAGE

ii

DEDICATION

iii

ACKNOWLEDGEMENTS

iv

ABSTRACT

v

TABLE OF CONTENTS

vi

LIST OF FIGURES

ix

LIST OF TABLES

xi

ABBREVIATIONS

xii

CHAPTER 1: INTRODUCTION

16

1.1 BIOLOGY OF BREAST CANCER
1.1.1 Etiology
1.1.2 Clinical impact of metastatic disease
1.1.3 EGFR and HER2 oncogenesis in breast cancer
1.1.4 Src in breast cancer
1.2 THE ACTIN CYTOSKELETON

19

1.2.1 Actin filament structure & dynamics
1.2.2 Actinbased structures of motility
1.2.3 Structure and signaling of invadopodia
1.3 SRC

31

1.3.1 History of Src research
1.3.2 Structure and regulation of Src
1.3.2 Src and cytoskeletal reorganization/regulation
1.4 CELLULAR REGULATION OF CDC42 AND NWASP ACTIVITY

35

1.4.1 Rho GTPases
1.4.2 Cdc42 Functions and Effector Proteins
1.4.3 NWASP Family and Regulation
1.5 CIP4 AND THE FBAR FAMILY

41

1.5.1 Characterization of CIP4
vi

1.5.2 BAR Domains and membrane curvature
1.5.3 TOCA1 and Actin Polymerization
1.6 HYPOTHESIS AND MODEL

45

CHAPTER 2: SRC PROMOTES MIGRATION AND INVASION OF BREAST
CANCERS

48

2.1 INTRODUCTION
2.2 MATERIALS AND METHODS

49

2.2.1 Cell Culture
2.2.2 Viability and Proliferation Assays
2.2.3 Statistics and Combination Index
2.2.4 Immunoblotting
2.2.5 Cell Cycle and Cell Death Assays
2.2.6 Immunofluorescence and Invadopodia Imaging
2.2.7 Migration and Invasion Assays
2.3 RESULTS

53

2.3.1 Dasatinib inhibits proliferation and metabolism of
MDAMB231 cells
2.3.2 Src inhibition does not correlate with proliferative
inhibition by dasatinib
2.3.3 Dasatinib treatment induces G1 arrest in MDAMB231 cells
2.3.4 Combination treatment of dasatinib and doxorubicin
synergistically inhibits metabolism
2.3.5 Dasatinibsensitive cells undergo cytoskeletal contraction
2.3.6 Migration and invasion are inhibited by dasatinib treatment
2.4 DISCUSSION

72

CHAPTER 3: CIP4 IS REQUIRED FOR MIGRATION AND INVASION OF

76

BREAST CANCER CELLS
3.1 INTRODUCTION
3.2 MATERIALS AND METHODS

77

3.2.1 siRNAmediated knockdown of CIP4 and NWASp expression

vii

3.2.2 Immunofluorescence and Invadopodia imaging
3.2.3 Migration and Invasion Assays
3.2.4 Acceptorphotobleaching FRET
3.3 RESULTS

80

3.3.1 Invasive breast cancer cell lines express high levels of CIP4
3.3.2 CIP4 promotes cellular migration in MDAMB231 cells
3.3.3 CIP4 controls NWASp activation in response to EGF
3.3.4 CIP4 promotes invasion of MDAMB231 cells in vitro
3.3.5 CIP4 localizes to invadopodia, but is not essential to their formation
3.4 DISCUSSION

92

CHAPTER 4: GENERAL SUMMARY

95

CHAPTER 5: FUTURE DIRECTIONS

99

REFERENCES

102

VITA

120

viii

LIST OF FIGURES

Page

CHAPTER 1
Figure 1: Arp2/3 promotes actin polymerization

22

Figure 2: Cytoskeletal structures of motility

25

Figure 3: Formation of invadopodia over gelatin substrate

28

Figure 4: Signaling pathways of invadopodia formation

30

Figure 5: Structure and regulation of c‐Src

33

Figure 6: Src‐dependent signaling pathways

34

Figure 7: N‐WASp structure and regulation

38

Figure 8: Structure and isoforms of CIP4

40

Figure 9: F‐BAR family of proteins

42

Figure 10: Ribbon diagram of dimerized BAR domains

43

Figure 11: Proposed model of CIP4‐mediated invadopodia formation

47

CHAPTER 2
Figure 12: Dasatinib inhibits cell proliferation in sensitive cells

54

Figure 13: Dephosphorylation of Src in response to dasatinib

56

Figure 14: Basal Src activity does not correlate with sensitivity

57

Figure 15: Dasatinib induces cell cycle arrest in sensitive cells

59

Figure 16: Synergistic anti‐proliferation with dasatinib and doxorubicin

6162

Figure 17: Doxorubicin cell cycle arrest dominantes dasatinib

65

Figure 18: Dasatinib induces cytoskeletal deregulation in sensitive cells

66

Figure 19: Effects of dasatinib on cytoskeletal proteins

67

Figure 20: Dasatinib impairs migration and invasion of MDA‐MB‐231

69

Figure 21: Invadopodia and invasion impaired with dasatinib, doxorubicin
combination

71

CHAPTER 3
Figure 22: Overexpression of CIP4 in invasive breast cancer cell lines

81

Figure 23: Upregulation of CIP4 mRNA in triple‐negative cell lines

82

ix

Figure 24: Subcellular localization of endogenous CIP4
Figure 25: Depletion of CIP4 impairs migration, not proliferation

83
8485

Figure 26: CIP4 interacts and increases activation of N‐WASp downstream of
EGFR

86

Figure 27: CIP4 enriched at invadopodia of MDA‐MB‐231 cells on gelatin

87

Figure 28: CIP4 required for formation and function of invadopodia

89

Figure 29: CIP4 required for basal and EGF‐dependent invasion

9192

CHAPTER 4
Figure 30: Proposed model of CIP4‐mediated invadopodia formation (repeated)

x

198

LIST OF TABLES

Page

Table 1: Comparison of podosomes and invadopodia

27

Table 2: Viability and proliferation of dastinib‐treated cells

55

Table 3: Synergy between dasatinib and doxorubicin

63

Table 4: Comparison of invasive and non‐invasive breast cancer cell lines

80

xi

ABBREVIATIONS
7‐AAD

7‐Amino‐actinomycin D

apFRET

Acceptor photobleaching FRET

Arp2/3

Actin‐related proteins 2/3

ATP

Adenosine triphosphate

BrdU

Bromodeoxyuridine

BSA

Bovine serum albumin

Cdc42

Cell division control protein 42

CDK

Cyclin‐dependent kinase

CFP

Cyan fluorescent protein

CI

Combination index

CIP4

Cdc42‐interacting protein 4

CME

Clathrin‐mediated endocytosis

CRIB

Cdc42/Rac‐interactive binding

CSF‐1R

Colony stimulating factor 1 receptor

Csk

c‐Src kinase

DMSO

Dimethyl sulfoxide

ECM

Extracellular matrix

EFC

Extended FCH (Fes/CIP4 homology)

EGFR

Epidermal growth factor receptor

ELISA

Estrogen receptor

ERM

Exrin‐radixin‐moesin

F‐BAR FCH

(Fes‐CIP4 homology)‐ BAR (Bin‐Amphiphysin‐Rvs)

xii

FAK

Focal adhesion kinase

FBP17

Formin binding protein 17

FCH

Fes/CIP4 homology

FITC

Fluorescein isothiocyanate

FRET

Fluorescence resonance energy transfer

GAP

GTPase‐activating protein

GDP

Guanosine diphosphate

GEF

Guanine nucleotide exchange factor

GTP

Guanosine‐5'‐triphosphate

HB‐EGF

Heparin‐binding EGF‐like growth factor

HER2

Human Epidermal growth factor Receptor 2

HGF

Hepatocyte growth factor

HNSCC

Head and neck squamous cell carcinoma

HR1

Homology region‐1

I‐BAR

Inverse‐BAR (Bin‐Amphiphysin‐Rvs)

IC50

Half maximal inhibitory concentration

IL‐8

Interleukin‐8

MAPK

Mitogen‐activated protein kinase

mDia

Mammalian Diaphanous‐related

MLC

Myosin light chain

MMP‐2,‐9

Matrix metalloproteinase‐2, ‐9

mRNA

Messenger ribonucleic acid

MTOC

Microtubule‐organizing center

xiii

MTT

3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide

N‐WASP

Neuronal‐WASP (Wiskott Aldrich Syndrome protein)

NFκB

Nuclear factor‐kappaB

p130CAS

p130(Crk‐associated substrate)

PARP

Poly(ADP‐ribose) polymerase

PDGFR

Platelet‐derived growth factor receptor

PI

Propidium iodide

PI3K

Phosphoinositide 3‐kinase

PI(4,5)P2

Phosphatidylinositol 4,5‐bisphosphate

PIP3

Phosphatidylinositol (3,4,5)‐trisphosphate

PR

Progesterone receptor

ROCK

Rho‐associated coiled‐coil‐forming protein kinase

ROI

Region of interest

RSV

Rous sarcoma virus

SFK

Src family kinase

SH2,SH3

Src homology 2,3

siRNA

Small interfering RNA

STAT3

Signal transducer and activator of transcription 3

TGFα

Transforming growth factor alpha

Tks5/FISH

Tyrosine kinase substrate 5/five SH3 domains

Toca‐1

Transducer of Cdc42‐dependent actin assembly

TRITC

Tetramethyl rhodamine iso‐thiocyanate

Tyr

Tyrosine

xiv

WAS

Wiskott Aldrich Syndrome

WASP

Wiskott Aldrich Syndrome protein

WAVE

WASP family verprolin‐homologous protein

WH2

WASP homology domain‐2

WIP

WASP‐interacting protein

YFP

Yellow fluorescent protein

xv

CHAPTER 1: INTRODUCTION
1.1 BIOLOGY OF BREAST CANCER
1.1.1 Etiology
Breast cancer is the most commonly diagnosed cancer in American women,
affecting nearly 200,000 new patients every year. Currently, there are more than 2.5
million women living in the US with a history of breast cancer diagnosis. Five‐year
survival rates for patients diagnosed with localized or regional disease are encouraging:
98.3% and 83.5%, respectively. However, for the women presenting with metastatic
disease, the five‐year survival drops to a dismal 23.3% (2). Thus, targeting of metastatic
disease represents an important area of research with strong clinical implications.
Although having a mother or sister with breast cancer significantly increases a
woman’s risk of developing breast cancer (3), less than 5% of breast cancer cases can be
attributed to family history of the disease (4, 5). This leaves the vast majority of breast
cancers as occurring due to environmental effects or unknown genetic factors. Age is a
primary risk factor; 65% of patients are over the age of 55 at diagnosis (2). Hormone
therapy, ionizing radiation, breast density, obesity, and excessive alcohol intake all
increase the lifetime risk of developing breast cancer, whereas pregnancy (especially
early), breast‐feeding, and exercise are associated with decreased risk (6, 7). Many of
these risk factors hinge on the role of hormones, especially heightened levels of estrogen,
in the development of breast cancer (8).
In general, cancer is defined as the uncontrolled growth of cells, which may or may
not spread to other parts of the body. The seminal paper by Hanahan and Weinberg
describes the “Hallmarks of Cancer”: uncontrolled growth, evasion of death (apoptosis),
self‐sufficiency in growth signals, insensitivity to anti‐growth signals, angiogenesis, and
tissue invasion/metastasis (9). Through a variety of mechanisms, cancer cells acquire
these basic capabilities in a multi‐step process known as tumorigenesis.
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As a whole, “breast cancer” is really a collection of diseases with a wide array of
etiologies. Tumors arise from the epithelial cells of the mammary ducts (ductal
carcinoma) or glands (lobular carcinoma). However, this histological distinction does not
correspond with the clinically important molecular subtypes (10). Recent molecular
profiling further separates breast cancers into subtypes based on gene expression
signatures. Cancers of the luminal subtype express hormone receptors and, due to newer
targeted therapies, have a generally good prognosis. In contrast, basal type tumors lack
estrogen and progesterone hormone receptors, making them refractory to popular
targeted therapies. This combined with the higher rate of aggressiveness and
invasiveness associated with basal tumors leads to a generally poor prognosis (10).
Overlapping this basal subtype are the “triple‐negative” cancers, which lack the estrogen
and progesterone receptors (ER and PR, respectively) as well as the human epidermal
growth factor 2 (HER2/neu/ErbB2), and are currently the subject of intense research.
Identification of this three‐gene signature is clinically important in assigning therapy
regimens, although some studies now suggest an expansion to five genes with the
inclusion of epidermal growth factor receptor 1 (EGFR) and cytokeratin 5/6 (11). Cancer
stem cell populations have been identified in breast cancers, and these subtypes might
represent tumors arising from stem cells at different stages of differentiation (10).

1.1.2 Clinical impact of metastatic disease
Metastatic tumors in organs distant from the primary cancer account for the
majority of breast cancer deaths. Fewer than 5% of patients diagnosed with metastatic
breast cancer achieve complete remission (12). Early‐stage, non‐invasive breast cancers,
or ductal carcinoma in situ (DCIS), are diagnosed in nearly 50,000 women every year,
with approximately 30% of these patients presenting with invasive disease in the
ipsilateral breast within the next 6 to 10 years (12). Identification of biomarkers to
predict the occurrence of invasive disease would have a profound impact on the
treatment of these patients. Additionally, treatment plans for women diagnosed with
locally invasive disease could be tailored based on these markers, advising whether
localized radiation or systemic therapy is more suitable. These methods would spare
17

many patients from the unnecessary toxicity of systemic chemotherapies and target only
the most high‐risk patients with aggressive treatments. Furthermore, identification of
pro‐invasive pathways also presents novel targets for the development of anti‐metastatic
therapies best suited to these early‐stage and locally invasive subtypes.

1.1.3 EGFR and HER2 oncogenesis in breast cancer
Oncogenes are mutated genes that promote tumorigenesis. In breast cancer, the
family of ErbB receptor tyrosine kinases (RTKs) are potent oncogenes whose expression
in tumors inversely correlates with the clinical prognosis (13). The epidermal growth
factor receptor (EGFR/HER1/ErbB1) is activated by its ligand, EGF (as well as TGFα,
HB‐EGF,

amphiregulin,

and

others)

upon

which

it

dimerizes

and

becomes

phosphorylated. Active EGFR dimers trigger downstream signaling pathways with a wide
range of outcomes, including proliferation, survival, and migration. Classically, EGFR
activates the PI‐3K/Akt and Ras/Raf/MAPK pathways. Activation of Akt leads to cell
survival via phosphorylation and inhibition of the pro‐apoptotic Bcl‐2 family of proteins
and cell cycle arrest through inactivation of the p21 and p27 cell cycle inhibitors. EGFR
can also activate the STAT family of transcription factors, specifically STAT3 in breast
cancer, promoting transcription of genes for proliferation (c‐myc) and cell‐cycle
progression (p21 and cyclin D1) (14). In addition to the classical signaling cascades
resulting from EGFR activation, EGFR can also translocate to the nucleus to act directly as
a transcriptional regulator (14). Overexpression as well as the appearance of activating
mutations in EGFR has been identified in a variety of cancers, leading to the development
of several EGFR‐targeted inhibitors. Specific small molecule inhibitors of EGFR, such as
gefinitb (Iressa®; AstraZeneca) and erlotinib (Tarceva®; Genentech) are approved for
treatment of lung and metastatic colorectal cancers, but have shown only moderate
effects in various trials for breast cancer.
The second member of the ErbB family, HER2/neu (ErbB2) has no identified
ligand, but is activated by heterodimerization with other family members. Functioning as
a co‐receptor with the other ErbB receptors, many of the transformative signaling
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pathways activated by EGFR are also activated by HER2. However, ligand dissociation
rates from HER2‐containing heterodimers are slower than without HER2, leading to
prolonged ErbB signaling (15). Amplification and/or overexpression, which occur almost
entirely in ductal carcinomas, are found in approximately 20‐30% of invasive breast
cancers (16, 17). Activating mutations may also be present which lead to constitutive
activation. Overexpression of HER‐2/neu is associated with more aggressive disease,
faster proliferation, and decreased sensitivity to chemotherapy. Anti‐HER2 therapies such
as trastuzumab (Herceptin®; Genentech) have had high rates of success in HER2‐
overexpressing cancers.

1.1.4 Src in breast cancer
The Src family kinases (SFKs) are involved in the regulation of many signaling
pathways affecting cell growth, migration, adhesion, and survival. (18‐21). C‐Src is the
cellular homolog of the potent v‐Src oncogene identified as the transforming protein
encoded by the Rous Sarcoma Virus. (RSV). Hyper‐activation or overexpression of Src
kinases is associated with transformation through increased proliferation and decreased
cell‐cell adhesion (22‐25, 26, 27) . Breast cancers exhibit significantly increased tyrosine
kinase activity compared to normal breast tissue, most of which can be attributed to
elevated activation of c‐Src (28, 29). Activating mutations in Src may result in increased
kinase activity (up to 20‐fold) with or without a concomitant increase in protein
expression (29‐32). Src associates with several oncogenes in breast cancer, including Her‐
2/neu and EGFR, and amplifies the transformative signaling (33‐35). Src is commonly
overexpressed with EGFR overexpression (33).
Treating breast cancer cells with Src‐targeted inhibitors (dominant‐negative proteins or
pharmaceutical inhibitors) decreases cell proliferation and migration in a variety of
human cancer cells, including breast cancer (36‐40).

1.2 THE ACTIN CYTOSKELETON
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Many cellular functions, including maintenance of cell shape, polarity, division,
adhesion, intracellular trafficking, and motility are dependent on the cytoskeletal system.
The cytoskeleton can translate cues from the extracellular environment into changes in
gene expression and differentiation. The structural and regulatory components of the
cytoskeleton are highly conserved across all organisms, attesting to its importance in the
most basic cellular functions. Because the cytoskeleton utilizes a system of multimeric
filaments, it can rapidly respond to changing extracellular cues to change shape by
rearranging the building block subunits. Migrating cells generate discrete structural
organelles, such as lamellipodia, podosomes, and invadopodia, which are driven by the
force of elongating cytoskeletal filaments. Many accessory proteins participate in the
regulation of filament dynamics, linking the intracellular signaling to a functional output
(41‐44).
In addition to providing the mechanical drive for cellular migration, the actin
cytoskeleton also provides the forces required for endocytosis, pathogen invasion,
cytokinesis, and organelle transport within the cell. Studies of actin “comets” used for
propulsion by invasive Listeria in mammalian cells have provided excellent models for
investigating the molecular requirements of actin filament polymerization (45).

1.2.1 Actin filament structure and dynamics
The actin cytoskeleton, like the microtubules, is a dynamic system of small,
diffusible subunits that self‐assemble into polarized filaments with a dynamic (plus) end.
Individual chains are then cross‐linked by accessory proteins into larger structures to
create specialized mechanical or functional organelles (41, 43, 45).
Components: Actin filaments (microfilaments) are 2‐stranded, helical filaments
built from globular actin monomers (G‐actin). These are the thinnest and most flexible of
the cytoskeletal filaments, with a diameter of approximately 5‐9 nm. Actin filaments not
only provide tracks for intracellular trafficking, but also are critical in the force generation
required for cellular motility and shape change. Each actin monomer added to the
filament is bound to a molecule of ATP, which is hydrolyzed by the enzymatic G‐actin after

20

its incorporation. Filamentous actin (F‐actin) is dispersed throughout the cell, but is
highly concentrated at the cortex, a region just below the plasma membrane, allowing for
rapid formation of migratory protrusions at the cell surface. Traditionally, the more
dynamic plus end has been termed the “barbed” end and the more stable, minus end the
“pointed” end (41, 43, 45).
Kinetics: Filament formation occurs in three main phases: nucleation, elongation,
and steady state. Although subunits will self‐assemble spontaneously, small oligomers are
highly unstable and will dissociate before elongation can proceed. This initial “seeding” of
the nascent filament is the rate‐limiting step or “lag‐phase”.
Once successful nucleation has occurred, subunits will rapidly assemble in the
“growth‐phase.” The filament will continue to elongate until it reaches the “equilibrium
phase,” a steady state in which subunits will continue to assemble and disassemble
without changing the length of the filament. In a phenomenon known as treadmilling,
subunits are added and progress through a filament when both ends of the filament are
exposed and are in areas of unequal critical concentrations, allowing subunit addition at
one end at the same rate at which the opposite end is losing subunits. This activity is
important to the dynamic responsiveness of the actin network. In response to a stimulus,
a small shift in the rates of association or dissociation can produce a rapid change in
filament length. By coupling spontaneous assembling filaments to the plasma membrane,
cells have developed a method of using very little energy to accomplish energetically
unfavorable mechanical work (41, 45).
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Figure 1: Arp2/3 complex promotes actin polymerization
through dendritic nucleation. Arp2/3 complex of proteins
facilitates nucleation of nascent actin filament, resulting in a
branched actin structure with filaments at 70‐degree angles.
Nucleation: Spontaneous nucleation of nascent filaments is a slow process, but can be
facilitated by accessory proteins (Figure 1). There are three primary proteins which
promote actin nucleation: the Arp complex, the formin proteins, and spire. Formins,
which include mDia1 and mDia2, dimerize via shared FH2 domains to form a ring
structure from which actin filaments spontaneously elongate. The formin ring remains
bound to the growing plus‐end and moves processively, blocking access by other capping
proteins. Regulatory inputs by signaling molecules can alter the function of formins at the
plus‐end. Spire functions as a single protein that contains four WH2 domains to bind and
stabilize a tetramer of actin monomers. After elongation, spire dissociates from the
filament, but can re‐bind to cross‐link actin filaments with microtubules (42).
The best‐characterized nucleator of actin filaments, however, is the Arp complex
(Arp 2/3), an aggregate of 7 proteins. Arp 2 and Arp 3 are structurally similar to actin
monomers and mimic a stable actin dimer. Five structural Arp proteins (ArpC 1‐5)
support the pseudo‐dimer. Although the Arp 2/3 complex can promote nucleation freely,
actin filaments are often formed from Arp complexes bound to the side of existing actin
filaments. This model of dendritic nucleation describes the ability of Arp complex to
initiate new branches of actin that protrude off the mother filament at a 70o angle,
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forming web‐like networks. In migrating cells, this multi‐directional polymerization
allows the cell to more quickly respond to extracellular cues and “steer” in any direction
by altering the localized activation state of the Arp complex (41‐44, 46, 47).
Organization of individual filaments into larger structures requires cross‐linking
accessory proteins. Actin filaments can be arranged in to either bundles of closely tied,
parallel fibers or looser webs of short filaments with more flexibility. Stress fibers are
contractile actin bundles linked together by alpha‐actinin and myosin to provide tension
between the cytoskeleton and anchoring focal adhesions. Web‐like networks of actin
interlink short actin filaments at right angles to provide a flexible rigidity to the cell
periphery. Filamin‐actin networks are found in lamellipodia and are required to maintain
a migratory phenotype (41‐44, 46).
These actin structures must be tied to the plasma membrane for effective shape
change. This function is provided by the ERM family of proteins, named for the three
charter members: ezrin, radixin, and moesin. These proteins contain a conserved actin‐
binding C‐terminus and an N‐terminal domain that anchors to transmembrane
glycoproteins. Commonly, this is CD44, the receptor for the extracellular matrix
component hyaluronan. ERM proteins exist in 2 conformations, open and closed,
depending on intracellular cues. Elevated levels of PIP2 open the conformation, permitting
oligomerization and cross‐linking (41‐44, 46).

Membrane associated proteins are

discussed in more detail in section 1.5.2.

1.2.2 Cytoskeletal structures of motility
Cellular migration and invasion are critical to the development and survival of any
organism. During embryogenesis, cells migrate, individually and as epithelial sheets, as
they differentiate into new tissues. Notably, individual neural crest cells migrate long
distances along the neural tube to colonize a wide variety of cell types in vertebrates.
Gastrulation, the process in which the three embryonic germ layers are positioned,
requires sheets of cells to move in a coordinated fashion. But these cell migrations are not
limited to development; there are many motile cells that maintain the adult body as well.
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Lymphocytes such as macrophages and neutrophils must home to sites of bacterial
invasion, osteoclasts and osteoblasts crawl through bone, degrading and replacing tissue,
and fibroblasts roam the stroma remodeling collagen networks. With the singular
exception of swimming sperm, all motile cells in the human body migrate by crawling, a
process which requires a dynamic and responsive network of sensors, signaling
molecules, and structural filaments (41, 44, 48).
While the protrusive force at the leading edge of a migrating cell is provided by
elongation of actin filaments, the microtubule network is also critical for efficient cell
movement. Polarity is a pre‐requisite for directional migration, and microtubules provide
the asymmetric network that reorients the Golgi towards the leading edge. While
disruption of microtubules does not impair the formation of protrusions, their
distribution is scattered and does not result in a net directional migration. This is the
result of lost polarity in signaling pathways and intracellular trafficking. Cdc42 activation
not only controls actin polymerization, but also induces microtubule polarity and
centrosome reorientation through the Par6/aPKC (atypical protein kinase C) complex
(49, 50). Microtubules, as well as intermediate filaments, contribute to the turnover of
adhesions, which is necessary for cellular migration.
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Figure 2: Cytoskeletal structures of motility. A) Three‐dimensional rendering of a cell as it
migrates across and invades a matrix‐like substrate. The lamellipodium, which is enriched in highly
branched actin filaments, is at the leading edge of the cell. From the lamellipodium emerge
filopodia, sensory structures of bundled actin. Contractile stress fibers terminate at focal
adhesions, which are being dissolved at the trailing edge of the cell. Invadopodia, also formed of
bundled actin, emanate from the ventral face of the cell to invade and degrade the gelatin
substrate. B) Higher‐magnification view of an active invadopodia as it degrades a layer of FITC‐
gelatin. Bundled actin stretches the length of the invadopodia, but is dependent upon the
branched actin at the base within the cell body.

Specialized structural organelles are formed by both motile and non‐motile cells to
interact with the surrounding environment (Figure 2). Microvilli are short protrusions
of bundled actin from the apical face of absorptive epithelial cells in the gut, which greatly
increase the available cell surface. Villin cross‐linking is specific to microvilli. Crawling
cells utilize a variety of specialized structural organelles to sense their environment and
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locomote forward (Figure 2). The initial phase of migration requires forward protrusion,
driven by polymerization and re‐organization of actin into uni‐ or multi‐dimensional
arrangements. Along the leading edge of a migrating cell, a broad, flat extension known a
lamellipodium expands out parallel to the substrate and adheres to propel the cell
forward. These structures have been well studied in frog and fish keratocytes,
demonstrating the dendritic nucleation model of Arp2/3‐mediated actin branching.
Microinjection of fluorescent‐actin into these structures has demonstrated array
treadmilling, in which the filaments turnover within the network (51). Just behind the
branched actin of the lamellipodium, resides a more stable, progressive lamellum. Ruffles
are similar sheet‐like protrusions of the membrane, but are distinguished from
lamellipodia by their lack of substrate adhesion, resulting in migration of the ruffle
rearward up the dorsal surface of the cell (42). Whereas lamellipodia provide the main
thrust of migration, filopodia serve as “directional sensors” to sense the extracellular
environment at the far leading edge. Filopodia are thin (less than 200nm in diameter),
finger‐like projections of bundled actin that are extended by migrating fibroblasts and
neural growth cones.
Three‐dimensional actin growth at the leading edge creates pseudopodia, which
are short protrusions seen primarily in amoebae and neutrophils. Adhesive structures
anchoring the migrating cell to the underlying substrate must also be dynamic; new
adhesions must be established at the leading edge of the lamellipodium while older
adhesions along the rear of the cell must be broken for retraction of the cell body.
Protruding lamellipodia that fail to adhere are swept up on the dorsal face of the cell as
membrane ruffles and carried back to the cell body. Focal adhesions link the extracellular
matrix to the stress fibers of the actin cytoskeleton via transmembrane integrins. Sensing
the substrate and tensions, integrins cluster and activate the focal adhesion kinase (FAK)
via Src (tyrosine kinase). This signaling pathway is critical for cell survival, growth,
proliferation, and migration (43, 52, 53).
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Table 1: Comparison of podosomes and invadopodia. Despite sharing many of
the same components, podosomes and invadopodia are differentiated by their
size, behavior, and the cells in which they are found.

Some adult cells must invade tissues to perform their normal functions. These cells
have developed specialized cytoskeletal structures to facilitate their unique method of
migration. Podosomes are finger‐like extensions found on the basal surface of the cell
that mediate adhesion to the extracellular substrate via integrins. Podosomes are built of
a central core of bundled F‐actin around which lies a characteristic ring of accessory
proteins that includes adhesion‐related proteins such as integrins and vinculin. Also
within the actin‐dense core are actin‐regulators such as (N‐)WASp and Arp2/3. Cortactin
is also present in podosomes, possibly acting as a scaffolding protein for N‐WASp and
Arp2/3 (54). Whereas podosomes are described primarily in monocyte‐derived cells such
as macrophages and osteoclasts, similar structures known as invadopodia have been
described in Src‐transformed fibroblasts and cancer cells (Table 1) (41, 42, 44, 54‐58).
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Figure 3: Formation of invadopodia over gelatin substrate. A) Formation of invadopodia
by breast cancer cell grown on FITC‐fibronectin substrate Reprinted with kind permission
from Springer Science+Business Media: Clinical and Experimental Metastasis,
Invadopodia: specialized cell structures for cancer invasion, 23, 2006, 97‐105, A.M.
Weaver, Figure 1. B) Electron micrograph of invadopodia invading gelatin layer from a
cancer cell. Scale bar = 500 nm. Reprinted from Current Biology, 18 (9), A.M. Weaver,
Invadopodia, R362‐4, Copyright (2008), with permission from Elsevier.

1.2.3 Structure and signaling of invadopodia
The terms podosome and invadopodium have been used interchangeably in
reference to protrusive structures formed by Src‐transformed fibroblasts (59‐61). Some
reports have speculated podosomes to be precursors to invadopodia, although no
evidence has been found to support this theory. Others argue them to be distinct
organelles, dependent on the cell type or extracellular environment. Invadopodia are
typically much larger, longer‐lived, and fewer in number. Both are enriched in matrix‐
metalloproteases, specialized proteins for ECM degradation, although invadopodia are
much more capable of degrading matrix (Figure 3) (41, 42, 44, 54‐58, 62, 63). Table 1
summarizes the common features and differences between podosomes and invadopodia
(54).
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Although the membrane protrusion of invadopodia is driven by bundled actin, this
structure is dependent on a base of branched actin similar to the actin structures found in
lamellipodia. Because of their similar structures, it’s no surprise that podosomes and
invadopodia would share many of the same actin regulatory proteins, including Arp2/3,
N‐WASp, cortactin, cofilin, and dynamin‐2. In addition to cortactin and N‐WASp, several
other Src‐targeted proteins, like FAK, p130Cas, and Tks5/FISH, are also common to both
(54, 58). A high concentration of phospho‐tyrosine is found in invadopodia (64),
suggesting elevated Src activity. In the dynamic podosomes, microtubules are critical to
their rapid turnover and patterning. The more stable nature of invadopodia, however,
limits their reliance on the microtubule network for formation. Intracellular trafficking
along microtubule networks may be necessary for delivery of proteinases for matrix
degradation (53, 54).
Cortactin: The role of cortactin in invadopodia formation has been studied in more
detail and is required for the early‐stages of formation (56, 65, 66). Studies have
implicated cortactin as a central scaffolding protein that brings together many of the
proteins required for invadopodia maturation (55, 56, 65, 67, 68). Cortactin, in synergy
with N‐WASp, potentiates Arp2/3 activation and stabilizes Arp2/3‐dependent branched
actin structures (69). More recently, Clark et al also demonstrated a role for cortactin in
targeting the metalloproteases MMP2 and MMP9 for secretion (56).

Cdc42/NWASp: Overexpression of components of this pathway, including Cdc42 and
Arp2/3 subunits, has been described in invasive mammary tumors (70). Using MTLn3
mammary rat adenocarcinoma cells, Yamaguchi (68) demonstrated that endogenous N‐
WASp localizes to invadopodia and is required for invadopodia formation (per siRNA and
dominant negative experiments).

Using a FRET‐based biosensor, Lorenz (71)

demonstrated that N‐WASP is unfolded, and therefore active, at the base of nascent
invadopodia.

Other WASP family members WAVE1 and WAVE2 do not localize to

invadopodia (68). Nck1, an upstream activator of N‐WASp, and WIP, the WASP‐
interacting protein which binds and stabilizes (N‐)WASp, also concentrate at invadopodia
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Figure 4: Signaling pathways of invadopodia formation. The WIP‐NWASp complex is
activated downstream of EGFR through Nck1 and Cdc42. Toca‐1 also increases N‐WASp
activation in response to curved membranes. N‐WASp activity promotes Arp2/3, leading to
branched actin nucleation, a requirement for early invadopodia formation.

and are required for their formation (68). Active, GTP‐bound Cdc42 is also required for
invadopodium formation (68).
In cultured cells, invadopodia are routinely identified by co‐localization of
degraded substrate with actin and cortactin. Similarly, N‐WASP and Cdc42 are co‐
localized with invadopodia (54, 55, 65, 68, 71).
EGFR: EGF stimulation promotes the formation of invadopodia, presumably
through this Cdc42‐N‐WASP pathway (Figure 4) (68, 71). EGF stimulation of cells
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expressing an N‐WASp biosensor elicits a spike in N‐WASp activation at the cell periphery
in response to EGF stimulus (71). Inhibition of EGFR (using AG1478) decreased
invadopodia formation in rat mammary adenocarcinoma cells (68). This correlates with
previous studies showing that EGFR inhibitors block invasion of cancer cells (72, 73).
Most recently, DesMarais et al demonstrated that cells preferentially form early stage
invadopodia on the side closest to an EGF source (74).
ECM remodeling: In addition to becoming motile, invading cancer cells also acquire
the ability to break through the basement membrane separating the tumor from the
endothelial cells of nearby blood vessels. Invadopodia are also sites of concentrated
protease secretion, allowing them to degrade the extracellular matrix and facilitate
cellular migration through a basement membrane (55, 68, 75, 76). ECM degradation is
mediated by matrix‐metalloproteases and both transmembrane proteases (MT1‐MMP
and seprase) and secreted proteinases (MMP2 and MMP9) are enriched at invadopodia
(56).
In vitro modeling: The formation of invadopodia can be visualized in detail in cells
grown in culture over a gelatin matrix (Figure 3), and studies have demonstrated a
strong correlation between formation of these structures in vitro and metastasis in vivo
(66, 77, 78). Only invasive tumor cells form Invadopodia, with the basal‐type breast
cancer cell line MDA‐MB‐231 being one of the most extensively studied human lines (54,
58). Most studies of invadopodia have been carried out using carcinoma cell lines,
specifically MTLn3 rat adenocarcinoma and MDA‐MB‐231 breast cancer cell lines.
However, invadopodia have also been observed in primary human HNSCC tumors
cultured on a fibronectin substrate (56). Recently, DesMarais et al also demonstrated the
formation of early stage invadopodia by MTLn3 cells grown on glass without any gelatin
or fibronectin substrate (74).

1.3 SRC
1.3.1 History of Src research
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The first form of Src (v‐src) was identified as the virally‐encoded transforming
gene responsible for chicken sarcomas. Peyton Rous isolated the causative virus in 1911
from filtered fluids extracted from the tumors and demonstrated the induction of new
tumors in healthy chickens injected with the virus. Infection of cultured cells also induced
transformation, leading to the search for the oncogenic mechanism of the virus, now
called Rous sarcoma virus (RSV). By 1977, the encoded v‐Src protein was isolated by Joan
Brugge and Ray Erikson, the first and one of the most potent oncogenes identified.
Transfection of v‐Src into cultured cells induces shifts in gene expression, alters cellular
morphology and adhesion, and increases migration.
Research by Michael Bishop and Harold Varmus identified a cellular form, dubbed
c‐Src, in normal chicken cells. This normal version of Src, homologs of which have been
identified in nearly every species, is known as a proto‐oncogene, the non‐mutated
precursor of an oncogene. Src was also the first tyrosine kinase to be characterized and
functions in a wide variety of signal transduction pathways. Under normal conditions, c‐
Src is non‐transforming. However, activating mutations in c‐Src can shift the regulatory
balance and induce some hallmarks of transformation such as anchorage‐ and growth
factor‐independent growth. The potent transforming effects of v‐src demonstrate the
need for tight regulation of this kinase in normal cells. Therefore, much subsequent
research focused on the comparative structure and regulation of the v‐ and c‐Src kinases
(79).
1.3.2 Structure and regulation of Src
The regulation of Src is dependent on its structure, which is comprised 2 protein‐
interaction domains, SH2 and SH3, and a catalytic domain (Figure 5). Activity of normal
c‐Src is tightly regulated through the auto‐inhibitory folding that results from the
intramolecular interaction between the short, regulatory domain at the carboxyl terminus
and the internal SH2 domain. This conformation is controlled by the balance of two
tyrosine phosphorylation sites: Tyr416 (Tyr419 in human Src) and Tyr527 (Tyr530 in
human Src). Phosphorylation of Tyr527/530 in the regulatory domain by Csk (C‐terminal
Src kinase) inactivates Src by maintaining the auto‐inhibitory interaction with the SH2
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Figure 5: Regulation of c‐Src. Intramolecular interactions between Tyr527 in the regulatory
domain and the internal SH2 domain, as well as between the SH3 and linker region, maintain
inactive Src in its closed conformation. Dephosphorylation of Tyr527 alleviates the interaction
and allows for auto‐phosphorylation of Tyr416 in the kinase domain of open, active Src.

domain. An additional intramolecular interaction between the SH3 domain and the short
linker region between the SH2 and catalytic domains further strengthens the closed
conformation. Tyr416/419 in the kinase domain is auto‐phosphorylated in active, open
Src. An analogous tyrosine residue is found within the activation loop of all other tyrosine
kinases. The constitutive activity of v‐Src results from the loss this tight regulation due to
the deletion of the regulatory domain, keeping Src in the open, active conformation.
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Figure 6: Src‐dependent signaling pathways. Src activity is critical to many signaling pathways, leading
to a wide variety of cellular functions, including mitogenesis, proliferation, survival, angiogenesis,
apoptosis, and actin reorganization. Active growth factor receptors, such as EGFR, promote Src
activation. Src may also be activated in complexes with FAK downstream of integrins.

1.3.3 Src and cytoskeletal reorganization
The tyrosine kinase function of Src is involved in many signaling pathways,
including those that control the cytoskeleton (Figure 6). The cytoskeleton plays a large
role in modulating the activity of Src. Intracellular localization of Src correlates with its
activation state. Inactive Src is sequestered at the perinuclear region of the cell in
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association with the microtubule network. However, active Src translocates to the plasma
membrane where it associates with actin via the SH3 domain. Myristilation at the amino‐
terminus also interacts with the plasma membrane. This translocation is not dependent
on an intact Src kinase domain (80). Src is recruited to focal adhesions through its
interaction with the Focal‐adhesion kinase (FAK), which stabilizes the open conformation
of Src and encourages Src activity. The FAK‐associated adaptor protein p130CAS may play
a similar role (81). Src‐null fibroblasts and osteoclasts have severe cytoskeletal defects,
including lost adhesion and rounding. These phenotypes can be rescued even by kinase‐
deficient Src mutants, indicating a kinase‐independent role for Src in maintaining the
cytoskeleton. However, rescue of migratory defects does require the activity of Src at the
plasma membrane and at focal adhesions (82). Phosphorylation of Src‐targets at
peripheral adhesion sites, such as FAK and p190rho‐GAP, is necessary for focal‐adhesion
turnover, a pre‐requisite of cellular migration. Fibroblast that are deficient in either FAK
or Src are non‐motile and have enlarged adhesions, presumably due to lost turn‐over
(81). FAK is also capable of phosphorylating N‐WASp at Tyr256 leading to actin
nucleation through the Arp2/3 complex (83). Additionally, cells that are lacking a kinase‐
competent Src are unable to polarize towards a chemoattractant (81).
Src also phosphorylates the actin cross‐linking protein cortactin, which stabilizes
Arp2/3‐mediated actin assembly (81). Src phosphorylation of cortactin decreases its
ability to bind actin, leading to impaired cytoskeletal rearrangement (84). Recent studies
of cortactin have demonstrated its central role in the organization of specialized invasive
structures (56, 65, 66).
1.4 CELLULAR REGULATION OF CDC42 AND NWASP ACTIVITY
1.4.1 Rho GTPases
The Rho family of GTPases is a subset of the larger Ras family of proteins, which
function as integration points for the control of cytoskeletal regulatory proteins. Rho
GTPases are important in many cellular functions, including cell cycle progression, cell
division, cell polarity, and migration. (Reviewed by (85) and (86)). Although there are
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over 20 known members of the Rho GTPase family, there are three that are well
characterized: Cdc42 (cell division cycle 42), Rac1 (Ras‐related C3 botulinum toxin
substrate 1), and RhoA (Ras homologous member A). These molecular switches are
downstream of several different G‐protein coupled receptors and receptor tyrosine
kinases (87)
Switching mechanism of small GTPases. GTPases exist in two states: the inactive,
GDP‐bound state and the active, GTP‐bound state. In the active state, GTPases bind and
regulate effector proteins. Upon hydrolysis of the bound GTP molecule, the GTPases
revert to an inactive conformation. Although GTPases possess the intrinsic ability to
hydrolyze GTP, specific GTPase‐activating proteins (GAPs) promote GTPase hydrolytic
activity and subsequent inactivation. Alternatively, guanine nucleotide exchange factors
(GEFs) catalyze the opposite reaction, in which a GDP molecule is exchanged for a GTP
molecule to activate the GTPase again. Activation of small GTPases is blocked by guanine
nucleotide dissociation inhibitors (GDIs), which sequester GDP‐bound forms of the small
G proteins in the cytosol. Constitutively active GTPase mutants impair the hydrolytic
activity of the GTPases, thereby locking them in the GTP‐bound state (85, 86, 88).
Rho GTPase activation induces a variety of cellular behaviors, including
transcriptional regulation and cell cycle progression. Cytoskeletal reorganization for
polarity and migration are heavily dependent on the regulation provided by RhoGTPases.

1.4.2 Cdc42 Functions and Effector Proteins
Polarity Polarization is fundamental to many cellular processes, including division,
secretion, and migration, and is typically dependent on external signals. Polarity is also
established by localized recruitment of Cdc42 to activated receptors, as well as activated
cell adhesion molecules (89). Cell‐cell contact activates Cdc42 through nectin and E‐
cadherin leading to generation of apical and baso‐lateral surfaces (90). Cdc42 is also
critical to the polarization of T cells towards the immunological synapse formed during
interaction with an antigen‐presenting cell. Upon activation of the T‐cell receptor, Cdc42
and its effector protein WASP are recruited to promote localized actin polymerization and
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generation of the synapse. Additionally, the MTOC and Golgi are re‐oriented towards the
synapse for the delivery of secretory vesicles, a process that is dependent on Cdc42
activity (89). Chemotactic cells also polarize in a similar manner to soluble factors.
Chemokines such as EGF and PDGF bind and activate cell surface receptors, recruiting
Cdc42 to the plasma membrane and activating Cdc42 via the Src pathway (91‐93). For
motile cells, the initial step in mesenchymal‐type migration is polarization to define the
regions of protrusion at the leading edge and retraction of the cell body at the trailing
edge.
Migration Active, GTP‐bound Rac accumulates at the leading edge of migrating
cells and establishes a positive‐feedback loop between PIP3 and PI3‐kinase (63).
Activation of PI3K results in increased PIP3 at the plasma membrane and activation of Rac
and Cdc42. In advancing lamellipodia, Rac induces actin polymerization via the effector
protein WAVE and activation of the Arp complex. Rac can also activate the LIM‐kinase in
lamellipodia to phosphorylate and inhibit cofilin activity effectively stabilizing actin
filaments. Downstream of Rac and Cdc42, the cross‐linking protein IQGAP may function to
stabilize the actin meshwork. Although Cdc42 is not required for formation of
lamellipodia, it does contribute to the protrusion of filopodia from the leading edge. This
occurs through the activation of the Cdc42 effector protein, N‐WASp, a promoter of
Arp2/3 activation and actin polymerization. Rho functions primarily in contractile forces
filaments and also participates in lamellipodia activity in hepatocyte growth factor (HGF)‐
stimulated KB cells. Interestingly, there is also complex cross talk between Rho, Rac, and
Cdc42. In general, the cell body retraction at the rear of the cell is dependent on Rho
signaling through ROCK and MLC phosphorylation to create actin‐myosin contractile
bundles (42, 86, 88).
Effector proteins Active GTPases mediate their responses through a wide variety
of effector proteins. Many of these proteins have been identified through yeast 2‐hybrid
screens and contain the classical Cdc42/Rac‐interactive binding (CRIB) domain. Rac and
Cdc42 share many of the same targets, such as IQGAP and PAK1‐3, which mediate actin
reorganization, cell‐cell adhesion, and stress‐fiber formation. Cdc42 plays a unique role in
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filopodia and invadopodia formation through its effects on the WASP/N‐WASP proteins
(85, 88).
1.4.3 NWASP Family and Regulation
WASP family Wiskott‐Aldrich Syndrome (WAS) is a rare, X‐linked disorder
characterized by eczema, thrombocytopenia, and immunodeficiency. Mutations in the
gene for the WAS protein (WASP) typically result in premature truncation of the protein,
leading to severe platelet and immune system defects. WASP expression is restricted to
hematopoietic cells, while the closely related neural‐WASP (N‐WASP) is ubiquitously
expressed. Another related set of proteins was named the WASP family verprolin
homologous protein (WAVE) 1‐3, also known as SCAR1‐3 (suppresses abnormalities of
cAR loss) (94, 95). N‐WASP was the first to be linked with actin polymerization as an
intermediate effector between Cdc42 and Arp2/3 (96).

Figure 7: N‐WASp structure and regulation. Intramolecular interaction between the
connecting regions (C) and the GTPase‐binding domain (GBD) maintain N‐WASp in a closed,
inactive state. Cdc42 and PI(4,5)P2 cooperatively relieve the inhibitory conformation,
activating N‐WASp. Open N‐WASp, which is accessible to phosphorylation by Src, is able to
activate Arp2/3 and induce actin polymerization.

Conserved across the five family members (WASP, N‐WASP, WAVE1‐3) is the C‐terminal
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WCA domain (Figure 7). This is actually a collection of three distinct regions, the WH2
(W) domain, a connecting region (C), and the acidic domain (A). N‐WASP is the only
family member that varies from this organization by having a second WH2 domain,
although its function is unknown. The WH2 domain, in close proximity to the Arp2/3
binding site within the acidic A region, binds actin monomers. The connecting (C) region
is responsible for the auto‐inhibitory folding conformation by binding to a central CRIB
domain. Binding of active Cdc42 to the CRIB (also known as GBD, GTPase binding domain)
displaces the C region, opening and activating N‐WASP (95, 97). Once open, N‐WASP can
bind Arp2/3, increasing Arp2/3’s affinity for ATP and promoting actin nucleation (47, 94,
98). Flanking the CRIB domain are poly‐lysine (BR, basic region) and poly‐proline
domains to which other regulatory proteins and adaptors bind. PI(4,5)P2 binds to the BR
and with Cdc42 can synergistically activate N‐WASP. SH3‐containing adaptor proteins
such as Nck2 and Grb2 bind the proline‐rich region, presumably to link N‐WASP to
activated receptor tyrosine kinases (RTKs) such as epidermal growth factor receptor
(EGFR). The tyrosine kinases Src and Fyn also bind here, although the function of N‐
WASP’s tyrosine phosphorylation sites is still not understood. N‐WASP may be able to
integrate the signaling pathways of GTPases with tyrosine kinases in the regulation of
actin nucleation (95, 97, 99, 100). The Cdc42‐interacting protein, CIP4, also interacts with
N‐WASP through the proline‐rich domain via its own SH3 domain (101, 102). The WASP
interacting protein (WIP) binds to N‐WASP at the WH1 domain and can interfere with
Cdc42‐mediated activation of N‐WASP (103). However, its presence also seems to be
required for efficient activation of N‐WASP by Toca‐1 (transducer of Cdc42‐activation‐1)
(104,

105).
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Figure 8: Structure and isoforms of CIP4. A) Domains and protein interactions of human CIP4a.
Amino acid positions are shown below each domain. MGD, I, and W are conserved residues
amongst CIP4 and Toca‐1. Mutations in MGD or I abrogate binding to Cdc42, where as mutation
of W in the SH3 impairs N‐WASp interaction. B) Structure of CIP4 isoforms. Dotted outline
represent mRNA, solid outline represents protein. Inserts, represented by triangles under CIP4a,
are the result of retained intronic sequences. Resulting isoforms are also diagramed.
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1.5 CIP4 AND THE FBAR FAMILY
1.5.1 Characterization of CIP4
The Cdc42‐interacting protein 4 (Figure 8a) was originally identified through
yeast‐2‐hybrid screens for novel binding partners of the RhoGTPase Cdc42 (101), WASP
(106), and the Src family kinase Lyn (102). It was immediately characterized by its unique
amino‐terminal coiled‐coil domain, which was termed FCH (FER‐CIP4 homology),
analogous to the coiled‐coil domain of the actin‐associated protein Cdc15 in S. pombe.
Subsequently, the carboxyl‐terminal SH3 domain was shown to interact with WASp and
mediate its binding to microtubules (106). Interaction between CIP4 and N‐WASp is
necessary for podosome formation in macrophages (107). Alternative isoforms of CIP4
have been identified that lack a functional SH3 domain due to retained intronic sequences
near the Cdc42 binding region (Figure 8b) (102, 108, 109).
The HR1 domain, an internal coiled‐coil motif with homology to the protein kinase
C, mediates binding of CIP4 to GTP‐Cdc42, not a classical Cdc42‐binding CRIB domain.
Point mutation of the isoleucine at 398 within the HR1 abrogated Cdc42 binding (106).
Two proteins closely related to CIP4 have since been identified, namely Formin binding
protein 17 (FBP17) and transducer of Cdc42 activation 1 (Toca‐1). These proteins share
similar FCH and SH3 domains and bind N‐WASp and dynamin via their SH3 domains
(Figure 9) (105, 110). Toca‐1 and FBP17 also share similar HR1 regions, however
mutation of the analogous isoleucine in Toca‐1 did not interrupt Cdc42 binding, but
required triple mutation of the adjacent MGD sequence (105). FBP17 does not bind Cdc42
(111). Toca‐1 also potentiates the Cdc42‐dependent activation of N‐WASp mediated actin
nucleation (105, 110). Functional studies of these proteins are still limited.
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Figure 9: F‐BAR family of proteins. Homology of CIP4, Toca‐1, and FBP17 at protein and
mRNA (parentheses) sequence levels. Significant conserved residues are noted: MGD and
isoleucine (I) residues in HR1 domain are necessary for Cdc42 binding. Conserved
tryptophan (W) is critical for N‐WASp interaction.

Recently, our understanding of the N‐terminal region has evolved greatly. Tsujita et al
demonstrated the weak homology of the coiled‐coil domain to the BAR (Bin‐amphiphysin‐
Rvs) family of proteins. Like other members of the BAR family, this structure can induce
the tubulation of membranes (112, 113). In tandem, the N‐terminal FCH and BAR regions
comprise the F‐BAR domain (also known as EFC for extended FCH), a subgroup of the
larger BAR family that is characterized by a shallower curvature (112, 114, 115). BAR
proteins (lacking the FCH) and I‐BAR proteins (inverse‐BARs) function by the same
mechanism, but have different degrees of curvature, producing different diameters of
membrane tubules (116, 117).
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Figure 10: Ribbon structure of dimerized BAR domains. From top: I‐BAR (IMD/IRSp53),
BAR/N‐BAR (endophilin), and F‐BAR (CIP4). Bottom diagram indicates individual helices and
FCH region of F‐BAR domains. Reprinted from Cell, 129, K. Fütterer and L.M. Machesky,
“Wunder” F‐BAR Domains: Going from Pits to Vesicles, 655‐657, Copyright (2007), with
permission from Elsevier.

1.5.2 BAR Domains and membrane curvature
Effective cell shape change requires not only the forces provided by the actin
cytoskeleton, but also molding of the cell membrane. Proteins of the BAR (Bin‐
amphiphysin‐Rvs) superfamily, which are capable of binding and/or inducing membrane
curvature, are the convergence point for RhoGTPase signaling, actin remodeling, and
membrane dynamics. The BAR structure that is shared by all members of the superfamily
is defined as a coiled‐coil region with a positively charged surface. The 3 repeated alpha‐
helices of each domain form a hydrophobic, curved structure (Figure 10) that mediates
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dimerization and interacts with the negatively‐charged lipid membranes, preferably
phosphotidylserine (118). In most members of the BAR family, this cationic face rests on
the concave side of a crescent‐shaped structure. This arrangement is typical of the
“classical” BAR and F‐BAR (FCH‐BAR) subfamilies, whereas proteins of the I‐BAR family
are inverted with a positively charged convex surface (Figure 10) (112, 114, 115). The
subfamilies of the BAR superfamily are characterized by the degree of curvature created
in the dimerized molecule, which specializes the proteins to a distinct membrane
structure. For instance, the BAR proteins are associated with endocytic vesicles, whereas
the F‐BAR proteins, which have a shallower curvature, are associated with the thinner
neck of vesicles as the separate from the plasma membrane (116, 119). The unique
inverted structure of I‐BAR proteins is associated with the opposite curvature found in
membrane protrusions (120, 121). Homologous proteins are conserved in yeast; Cdc15 in
fission yeast is found at the contractile acto‐myosin ring as daughter cells separate (122,
123).
Overexpression of BAR domains, either in isolation or within full‐length proteins,
is sufficient to induce membrane tubulation (112, 113, 124) However, some studies
suggest that BAR domains are “curvature sensing” and bind membrane which are already
deformed (125). These two arguments are not mutually exclusive: BAR domains binding
to curved membranes will be induced to dimerize, recruiting additional BAR‐containing
proteins, and in turn inducing additional membrane curvature (116). These mechanisms
may also be repeated in caveolae‐dependent endocytosis.
Aside from their membrane‐interacting regions, BAR proteins also commonly
associate with the actin cytoskeleton and cytoskeletal regulatory proteins such as N‐
WASp/WAVE and dynamin. The interaction between BAR proteins and the cytoskeleton
has been best described in clathrin‐mediated endocytosis, specifically in the recruitment
of dynamin to promote membrane scission (115, 126, 127). F‐BAR proteins CIP4 and
FBP17 both bind N‐WASp and dynamin‐2 via carboxy‐terminal SH3 domains. Toca‐1 and
FBP17 are both inducers of membrane curvature‐dependent actin polymerization (126,
127).

44

1.5.3 TOCA1 and Actin Polymerization
N‐WASp activation is dependent on its interaction with GTP‐Cdc42 and PIP2
(Figure 7a) (for detailed discussion, see section 1.4.3). Similar to CIP4, Toca‐1 binds GTP‐
Cdc42 through the internal HR1 motif and interacts with N‐WASp via the C‐terminal SH3
domain (105). Actin polymerization assays can be used to infer the activation state of N‐
WASp by quantifying the rate of pyrene‐actin assembly in cell‐free systems. Using this
method, Ho et al demonstrated that depletion of Toca‐1 from xenopus egg extracts
decreased N‐WASp‐mediated activation of Arp2/3 and actin polymerization (Figure 7b)
(105). Whereas purified wild‐type Toca‐1 rescued the phenotype, mutated Toca‐1
proteins, deficient in either N‐WASp or Cdc42 binding, were unable to restore actin
polymerization. A constitutively active mutant of N‐WASp does not require Toca‐1 to
induce actin polymerization, confirming that N‐WASp is downstream of Toca‐1 (105).
These results were also repeated by observing actin comet formation on the surface of
endomembrane vesicles in the presence of Toca‐1 depleted cell extracts (105). Takano et
al utilized liposomes to demonstrate that FBP17 and Toca‐1 induce activation of N‐WASp
(in complex with WIP) and actin polymerization that is dependent on membrane
curvature (127). Interestingly, this effect was dependent on a conserved sequence of
acidic residues adjacent to the SH3 domain, suggesting the conformation of FBP17/Toca‐
1 is critical to its function.
1.6 HYPOTHESIS AND MODEL
F‐BAR proteins are known to function at the plasma membrane to sense and
induce membrane curvature through dimerized BAR domains, amphipathic crescent
shaped regions at the N‐terminus. CIP4 and Toca‐1 also bind the RhoGTPase Cdc42
through a central HR1 domain and N‐WASp via their c‐terminal SH3 domains. While F‐
BAR proteins have typically been implicated in endocytosis, I propose that there is also a
role for the concave‐binding regions of F‐BAR proteins in membrane protrusion. FBP17,
which is closely related to CIP4 but unable to bind Cdc42, contributes to podosome
formation in macrophages (128). Toca‐1, which is structurally very similar to CIP4,
stimulates Arp2/3‐mediated actin polymerization through Cdc42‐dependent activation of
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N‐WASp (105). Cell‐free models demonstrated that liposome binding of FBP17 and Toca‐
1 increased N‐WASp‐mediated actin polymerization, suggesting a role for F‐BAR proteins
in cytoskeletal reorganization at curved membranes (127). The study by Takano et al
highlights the importance of an acidic region adjacent to the SH3 domain and presents a
model in which this motif repels the lipid bilayer, forcing the SH3 domain away from the
plasma membrane and the F‐BAR domain. Given the high degree of similarity between
CIP4 and Toca‐1, I propose that CIP4 functions in an analogous manner. The Corey lab
demonstrated that Src family kinases bind and phosphorylate CIP4 at a site adjacent to
this acidic motif. Therefore, it is likely that Src phosphorylation of CIP4 contributes to the
conformation of CIP4 by modulating the electrostatic repulsion.
My preliminary data indicates a correlation between CIP4 expression and the
invasiveness of breast cancer cell lines in vitro, suggesting that CIP4 might play a role in
cellular motility. Therefore, I propose a model in which CIP4 functions as a
scaffolding protein that facilitates NWASp activation by stabilizing the open
conformation, which increases its interaction with active Cdc42 at areas of
membrane curvature and leads to localized actin polymerization at invasive
cytoskeletal structures (Figure 11). In this model, CIP4 binds the lipid membrane,
dimerizes via the F‐BAR domains, and induces membrane curvature. Activation of EGFR
and Src leads to the phosphorylation of CIP4, strengthening the electrostatic repulsion
that forces the SH3 domain away from the membrane and the F‐BAR domain. This spring‐
like conformation acts as a scaffold to maintain the open conformation of N‐WASp by
tethering the poly‐proline region of N‐WASp away from the membrane‐bound basic
domain. By stabilizing this open conformation, CIP4 increases access by Cdc42 and Src to
the regulatory domains of N‐WASp, potentiating N‐WASp activation and leading to
Arp2/3‐mediated actin polymerization. Through this proposed mechanism, CIP4 targets
actin polymerization to areas of membrane curvature, a critical function in invadopodia
formation.
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Figure 11: Proposed model for the scaffolding role for CIP4 promoting N‐WASp activation at
invadopodia.
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CHAPTER 2: SRC PROMOTES MIGRATION AND INVASION OF BREAST CANCER CELLS
2.1 INTRODUCTION
c‐Src is a non‐receptor tyrosine kinase that is involved in many distinct signaling
pathways (Figure 6). The structure of Src combines a carboxy‐terminal kinase domain
with SH2 and SH3 interaction domains. This arrangement allows it to function as a kinase
within larger, multi‐protein complexes, most notably the FAK‐Src complex. In response to
ECM‐interaction, the focal‐adhesion kinase (FAK) is recruited to the cytoplasmic tail of β‐
integrins via talin and paxillin. β‐integrins also bind the SH3 domain of Src, encouraging
interaction between FAK and Src’s SH2 domain. FAK auto‐phosphorylation at Tyr397 is
associated with activation, although Src also phosphorylates FAK at multiple tyrosine
sites, including Tyr576 in the kinase domain and Tyr925. Paxillin is also phosphorylated
by Src. The FAK‐Src complex phosphorylates several targets leading to increased
migration and cytoskeletal rearrangement. The p130CAS (Crk‐associated substrate)
adaptor protein promotes migration after phosphorylation by FAK and Src (20, 33, 129).
Also downstream of FAK‐Src are Crk and the closely related CrkL, which interact with
p130CAS. Activation of CrkL induces Rac/Cdc42 signaling to promote integrin dependent
migration via WAVE/N‐WASp and Arp2/3 (20).
In addition to the integrin‐mediated c‐Src signaling through FAK, Src also
modulates signaling from receptor tyrosine kinases like EGFR, HER2, PDGFR, and CSF‐1R.
Src’s interaction and synergism with the oncogenic potential of EGFR have been well
described (33). After EGF‐induced dimerization and transphosphorylation of EGFR, Src is
recruited and phosphorylates the cytoplasmic tails of EGFR at Tyr 845 and Tyr1101. This
amplifies the activation of EGFR targets such as PI‐3K, Shc, and MAPK. PI‐3K signaling
through the Akt/IKK/NFκB cascade results in inhibition of apoptosis via caspase‐9
inactivation and cell survival. Furthermore, NFκB‐dependent increases in IL‐8 encourage
angiogenesis.
c‐Src encourages EGFR‐dependent tumorigenesis through potentiation of
signaling. Given that Src is overexpressed or hyperactive in a variety of human cancers,
Src‐targeted therapies have been widely investigated for the treatment of cancers. Several
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small‐molecule inhibitors that inhibit Src also inhibit the Abl tyrosine kinase due to the
structural similarity between their ATP‐binding domains. Dasatinib (BMS‐354825,
Sprycel

®,

[N‐(2‐chloro‐6‐methylphenyl)‐2‐[[6‐[4‐(2‐hydroxyethyl)‐1‐piperazinyl]‐2‐

methyl‐4‐pyrimidinyl]amino]‐5‐thiazole‐carboxamide] is a recently developed inhibitor
of Src/Abl that is orally active. Dual Src/Abl inhibitors like dasatinib were initially
approved for BCR‐Abl+ leukemias that were refractory to imatinib therapy. Like other
small‐molecule inhibitors, dasatinib is capable of inhibiting its target at low
concentrations, making it a more favorable clinical option. In vitro testing demonstrated
that the kinase activities of Src and Abl are 50% inhibited with less than 1.0 nM of
dasatinib. Increasing the dasatinib dose leads to inhibition of other tyrosine kinases (p38,
Akt, and FAK) and receptor tyrosine kinases (PDGFR, c‐kit, and Ephrin) (130). In lung and
prostate cancer cell lines, low‐dose (nanomolar) treatment with dasatinib inhibited
proliferation (37, 130‐132). Dasatinib has also shown mixed efficacy in breast cancer cell
lines: “triple‐negative” cell lines, which lack ER, PR, and HER2, are more sensitive to
dasatinib than other hormone receptor‐positive lines (133). However, the molecular
pathways mediating this selectivity have not been previously been investigated.
To identify the molecular pathways that differentiate dasatinib‐sensitive from
dasatinib‐resistant breast cancer cell lines, I investigated the effects of dasatinib on three
cell lines that had been previously screened for their response to dasatinib in growth
assays. Reliable measures of response are an important component in the clinical
evaluation of tumors treated with targeted therapies. Therefore, I also sought to identify
biomarkers for dasatinib response by examining the inhibition of key Src‐dependent
signaling pathways. Given the critical role Src pathways play in cytoskeletal
rearrangement, I evaluated the effects of Src inhibition on the migration and invasion of
dasatinib‐sensitive breast cancer cells.
2.2 MATERIALS AND METHODS
2.2.1 Cell Culture
Breast cancer cell lines were obtained from the ATCC via the labs of Drs Gordon
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Mills and Janet Price (MD Anderson Cancer Center, Houston, TX). All cell lines were
grown at 37oC and 5% CO2. MDA‐MB‐231 and T47D cells were grown in DMEM/F12
media (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum (Hyclone,
Logan, UT), 100 U/mL penicillin, and 100 μg/mL streptomycin. MCF7 cells were
maintained in MEM media (Invitrogen) supplemented with 10% fetal calf serum, 100
U/ml penicillin, 100 mg/ml streptomycin, 2mM L‐glutamine, 0.1mM non‐essential amino
acids, 1mM sodium pyruvate, and MEM vitamin solution.
2.2.2 Viability and Proliferation Assays
For cell counting and trypan blue exclusion, cells were grown in the appropriate
media plus dasatinib for up to 72 hours, collected by scraping, diluted in trypan blue dye,
and counted with a Brightline hemocytometer (Hausser Scientific, Horsham, PA).
Proliferation was determined using an MTT assay (#M5655, Sigma‐Aldrich, St. Louis, MO).
Cells were seeded at a density of 3‐5x103 cells per well of 96‐well plate with complete
medium 24 hours prior to treatment. Cells were then treated for 24, 48, and 72 hours
before MTT reagent was added and absorbance was read at 570nm, per manufacturer’s
instructions.
2.2.3 Statistics and Combination Index
Descriptive statistics including mean values and s.d. were calculated using Microsoft Excel
or Prism software (GraphPad, La Jolla, CA). Statistical significance was determined by
two‐sample student t‐tests (P1/40.05). Calculation of GI50 (Dm) values, measures of
sigmoidicity (m), correlation coefficients (r), and combination indices (CI) of multi‐drug
treatments were performed using the CalcuSyn software (Biosoft, Cambridge, UK). Degree
of cooperation between dasatinib and doxorubicin was determined from the combination
index (CI) as follows: CI >1 indicates antagonism; CI = 1 indicates additivity; 1 > CI > 0.3
indicates synergy; 0.3 > CI > 0.1 indicates strong synergy (134, 135).
2.2.4 Immunoblotting
Cells were grown in complete media overnight, treated with dasatinib for 2–48 h,
and washed in ice‐cold PBS. Whole‐cell lysates were obtained from cells collected by
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scraping, and lysed in 1% NP‐40 buffer supplemented with the appropriate proteinases
and phosphatase inhibitors. Protein concentrations were determined by a Bradford assay
and equal amounts of each sample were either prepared for loading by boiling in Laemmli
sample buffer. Western blot analysis was performed with whole cell lysates or
immunoprecipitated samples resolved by SDS–PAGE and transferred onto Immobilon‐P
Transfer Membranes (Millipore Corp, Billerica, MA, USA). The membranes were blocked
overnight with blocking buffer (5% milk or 5% BSA, depending on the antibody, with
0.1% Tween‐20). The blots were incubated with primary and then secondary antibodies
for 1 h each at room temperature. Immunoreactive bands were visualised by enhanced
chemiluminescence (Amersham, Piscataway, NJ, USA). Membranes were then stripped for
30 min at 371C using Stripping buffer (Pierce, Rockford, IL, USA), reblocked, and probed
for actin, GAPDH, or the nonphosphorylated protein being analysed as loading controls.
Densitometric analysis was performed using the NIH software, ImageJ (Macintosh
platform, Bethesda, MD, USA), to determine the ratio of phosphorylated protein to total
protein. For SrcpY416: c‐Src, IC50 values were calculated based on exponential
regressions of the plotted ratios using Microsoft Excel. For IC50 values of Src inhibition,
ratio values of Src‐pY416 to total Src were generated by exponential regression
(Microsoft Excel).
2.2.5 Cell Cycle and Cell Death Assays
Cell cycle distribution was analyzed by plating cells at a density of 3‐4x105 cells
per 10cm culture dish with complete medium 24 hours prior to treatment. Cells were
then treated with dasatinib for 48 hours, collected, fixed in 70% ethanol, washed, and
stained with a 5% propidium iodide solution. Samples were detected with a FACSCalibur
(Becton Dickinson, Franklin Lakes, NJ) and analyzed with FlowJo software (Tree Star, Inc.,
Ashland, OR). Annexin‐V and propidium iodine staining were performed with a flow
cytometric apoptosis detection kit (BD Pharmingen, San Jose, CA) per the published
manual and analyzed by FACSCalibur. BrdU and 7‐AAD staining and analyses were
performed per the manufacturer’s published protocols (FITC Flow Kit, BD Biosciences).
2.2.6 Immunofluorescence and Invadopodia Imaging
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Cells were grown and treated on glass chamber slides or glass coverslips, fixed in
4% formaldehyde, permeabilized with 0.1% TritonX‐100, blocked in 1% BSA, and stained
with anti‐alpha‐tubulin (Sigma, St. Louis, MO) and Alexa‐488 fluorescent phalloidin
(Molecular Probes, Carlsbad, CA). Tubulin staining was detected with a Cy3‐conjugated
donkey anti‐mouse antibody (Jackson ImmunoResearch). Slides were prepared using
ProLong Antifade mounting media (Molecular Probes), and imaged with a Nikon Eclipse
TE2000U microscope and MetaMorph imaging software (Molecular Devices, Toronto,
Canada). Invadopodia were analyzed by seeding cells on a thin layer of FITC‐labeled
gelatin (VWR, West Chester, PA) as previously described (56). Cells were allowed to
invade for 20 hours, and the slides were then processed as described above, stained first
for cortactin and then with Cy3‐anti‐mouse. Invadopodia were counted from 10 random
fields in each sample (blinded) and averaged.

2.2.7 Migration and Invasion Assays
Migration was measured by wound healing assay, in which cells were grown to
80% confluence in 6‐well plates, streaked with a sterile pipette tip, and allowed to
recover in dasatinib‐treated media. After 6 hours, plates were visualized at 10x
magnification and migration determined by measuring wound width (in pixels) using the
MetaMorph imaging software (Molecular Devices, Toronto, Canada). Invasiveness was
determined using Matrigel invasion chambers with an 8mm‐pore membrane (BD
Biosciences, San Jose, CA) seeded with 2.5x104 cells each. Dasatinib‐treated media was
used in both the upper and lower chambers, with serum added only to the lower
chamber. Cells were allowed to invade for 24 hours through the Matrigel, at which point
the inserts were removed and the membranes scrubbed and fixed in methanol. Invading
cells were then stained and mounted on slides with Prolong Antifade with DAPI
(Molecular Probes, Carlsbad, CA). Membranes were then visualized with an epifluorescent
microscope (Nikon, Tokyo, Japan), and quantification of invading cells (visualized as
DAPI‐stained nuclei) was determined in 6 random fields per sample.
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2.3 RESULTS
2.3.1 Dasatinib inhibits proliferation and metabolism of MDAMB231 cells
Building on the observations by Finn et al that triple‐negative and basal‐type
breast cancer cell lines were more sensitive to dasatinib (133), I compared three
representative breast cancer cell lines. MDA‐MB‐231 is a well‐characterized, triple‐
negative, basal‐subtype breast cancer cell line. MCF‐7 and T47D are luminal‐subtype
breast cancer cell lines that are positive for ER and PR. To determine the IC50 for the anti‐
proliferative effects of dasatinib, a dose‐response curve was created for each cell line by
treating cells with dasatinib for 48 hours and quantifying metabolic activity using an MTT
assay (Figure 12a). MDA‐MB‐231 cells were the most responsive (IC50 = 0.16 µM), while
T47D demonstrated moderate growth inhibition (IC50 = 0.45 µM) and MCF7 showed very
little response (IC50 = 12.3 µM). To confirm these results, cells were grown in dasatinib for
72 hours and counted at 24, 48 and 72 hours (Figure 12b). Again, MDA‐MB‐231 were the
most sensitive; a dose‐dependent increase in doubling‐time was significant (p<0.01) after
72 hours for all three doses (0.05 µM, 0.1 µM, and 1.0 µM), where as only the highest dose
for MCF7 was significant at 72 hours. Using cell‐counting data, the calculated IC50 values
for MDA‐MB‐231 and MCF7 cells were 0.33 mM and 0.99 mM, respectively, a three‐fold
difference in sensitivity. Again, T47D were moderately sensitive.
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Figure 12: Dasatinib inhibits cell proliferation in sensitive cells. A) MTT assay of
MDA‐MB‐231, MCF7, and T47D after dasatinib treatment. B) Cell counting for 72
hours of dasatinib treatment.
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Because the calculated IC50 values were higher when based on cell counting, I
examined the viability using trypan‐blue exclusion and replication rates using BrdU
uptake. Replicating MDA‐MB‐231 cells were significantly reduced from 35% to 12% with
100 nM dasatinib (Table 2), whereas the BrdU uptake rates were not significantly altered
in MCF7 or T47D cells. Interestingly, there was no significant decrease in viability of the
MDA‐MB‐231 cells upon dasatinib treatment. This lack of cell death was confirmed using
flow cytometric quantification of annexin‐V and PI staining (data not shown). This is also
demonstrated by western blotting for PARP cleavage products in whole cell lysates of
MDA‐MB‐231 cells (Figure 17b).

Table 2: Viability and proliferation of dasatinib‐treated cells.

2.3.2 Src inhibition does not correlate with proliferative inhibition by dasatinib
Previous studies of dasatinib have demonstrated that decreases in phospho‐Src
may serve as biomarkers for responsiveness (136, 137), however, this has not yet been
investigated in solid tumors. Therefore, I examined whether differential inhibition of Src
was a biomarker in the breast cancer cell lines. Src activation is regulated by the balance
of two main phosphorylation sites within in kinase domain: an activating site at Tyr416
(chicken

nomenclature)

and

Tyr527

(chicken),

an

inactivating

site

whose

phosphorylation maintains the inhibitory intra‐molecular interaction with the SH2
domain (129). Using the dose‐dependent dephosphorylation of Tyr416, I calculated the
IC50 values for Src inhibition in each cell line after 2 hours of dasatinib treatment. Despite
the disparity in response for proliferation, there were no significant differences in Src
inhibition between the three cell lines (Figure 13a). Dephosphorylation of Tyr416
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(>75%) was accomplished with less than 100 nM of dasatinib in all three cell‐lines, a dose
achievable in clinical trials (138). Therefore, the phosphorylation status of Src is not an
accurate biomarker for dasatinib‐response in breast cancer cells.

A

B

Figure 13: Dephosphorylation of Src in response to dasatinib. A) Phospho‐Src
Tyr416. B) Phospho‐Src Tyr527.

The activation of Src is dependent upon the balance of two phosphorylation sites,
the activating Tyr416 residue, as well as Tyr527, which maintains Src in it’s inactive,
closed conformation. I examined the phosphorylation status of this inhibitory tyrosine, in
response to dasatinib and found it to also be comparably inhibited across the three lines
(Figure 13b). While this could affect the overall inhibition of Src, dephosphorylation of
Src‐Y527 was only significant at the doses 10‐fold higher than that needed for Tyr416
inhibition.

At this level of dasatinib dosing, off‐target effects may be present like

inhibition of Csk (C‐terminal Src kinase) (139, 140).
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Figure 14: Basal Src activity does not correlate with sensitivity. A) Western blot for phospho‐Src
(Y416) and c‐kit in untreated cell lines. B) Dephosphorylation of Src in dasatinib‐treated MDA‐MB‐
468 cells. C) MTT assay shows dasatinib‐response of MDA‐MB‐468 cells.

Clinical applications of dasatinib will benefit from reliable predictors of response. To
determine whether basal Src activity might predict response to dasatinib, I compared
starting levels of phospho‐Src (Y416) in a panel of breast cancer cells including MDA‐MB‐
231, MCF7, and T47D (Figure 14a). Again, there were no dramatically different levels of
Src phosphorylation that correlated with dasatinib‐response. One cell line tested, MDA‐
MB‐468, demonstrated high levels of phospho‐Src (Y416), prompting me to check the
dasatinib‐responsiveness of this line. As with the initial three cell lines, phospho‐Src
(Y416) was completely inhibited by 100 nM dasatinib (Figure 14b), suggesting that the
high level of basal Src activity did not confer resistance to dasatinib. However, the IC50
based on metabolic inhibition (MTT assay) was greater that 10 µM (Figure 14c), similar
to the MCF7 line, classifying it as a dasatinib‐resistant cell line. Together, these results
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demonstrate that basal phospho‐Src levels and dasatinib‐dependent dephosphorylation
are not reliable markers of dasatinib sensitivity in breast cancer cell lines.
Because dasatinib has also been reported to inhibit c‐kit, PDGFR, and EphA2 (130,
141‐143), it is possible that the effects of dasatinib are dependent on their inhibition. To
this end, also screened the cell line panel for expression of these alternative targets. The
most‐sensitive cell line, MDA‐MB‐231, did not express c‐kit or PDGFR (Figure 14a) (144,
145), excluding them as potential targets. Again, only the MDA‐MB‐468 line expressed
high levels of c‐kit, also indicating that is not an appropriate predictive marker. The MDA‐
MB‐231 cells did express high levels of the Ephrin receptor, however, but dasatinib
treatment did not affect its phosphorylation status (data not shown) (146). Based on
these results, these alternative targets of dasatinib were also unreliable predictors of
response. However, it remains possible that other, unknown targets of dasatinib are being
inhibited and could prove to be effective predictors or markers or response.
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Figure 15: Dasatinib induces cell cycle arrest in sensitive cells. A) Cell cycle distribution
after dasatinib treatment. Cells were treated with indicated doses of dasatinib for 48 hours,
stained for DNA content, and analyzed by flow cytometry. Graphs illustrate the percentage
of the population in each phase of the cell cycle. ** represents p < 0.01 by t‐test. B)
Inhibition of pCdk2 and accumulation of p27 after dasatinib treatment. Accumulation of
Src‐targeted p27 and resulting inhibition of Cdk2 correlate with G1 arrest in dasatinib‐
sensitive MDA‐MB‐231 cells. C) Inhibition of Akt after dasatinib treatment.
Dephosphorylation of Akt in response to dasatinib correlates with cell cycle arrest, and
accumulation of p27, also a target of Akt.
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2.3.3 Dasatinib treatment induces G1 arrest in MDAMB231 cells
Because dasatinib impaired proliferation but did not result in cell death, I examined
whether dasatinib could block cell cycle progression, which has not been previously
demonstrated in solid tumors. Therefore, I employed flow‐cytometry to create cell cycle
distribution profiles for each cell line after 48 hours of treatment with dasatinib (Figure
15a). In keeping with the differences seen in proliferation, only the MDA‐MB‐231 cells
exhibited a significant increase in G1 phase cells (p<0.001). This cell cycle inhibition was
evident at 0.1 and 1.0 μM of dasatinib (57% and 64%, respectively, p<0.01 by t‐test), in
comparison to the DMSO control (41% in G1). MCF7 and T47D cells did not undergo any
significant cell cycle redistribution in response to dasatinib treatment. Supporting my
previous observations that there was no cell death associated with dasatinib treatment,
there was no significant accumulation of sub‐G1 cells in any cell line.
To further characterize the molecular pathways involved in the G1 arrest of MDA‐
MB‐231 cells, I performed western‐blots probing for the levels of phospho‐Cdk2
(activating) and p27Kip1, proteins involved in promoting G1 to S‐phase transition in cycling
cells (Figure 15b). Confirming the cell‐cycle data, only the MDA‐MB‐231 cells exhibited a
decrease in phospho‐Cdk2 after dasatinib treatment, an indicator of G1 arrest. Cdk2
activity is inhibited by p27, which is negatively regulated by Src through phosphorylation
and targeting for degradation. Following dasatinib treatment, p27 accumulation was only
seen in the MDA‐MB‐231 cells, explaining the decrease in Cdk2 activity. In addition to its
regulation by Src, p27 is also negatively regulated by Akt. Because Akt is also downstream
of Src, it is possible that Akt inhibition could contribute to p27 downregulation. To
examine whether Akt was inhibited in response to dasatinib, I probed cells for phospho‐
Akt and found that Akt was inhibited only in the MDA‐MB‐231 cells (Figure 15c).
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A

Figure 16: Synergistic anti‐proliferation with dasatinib and doxorubicin. A) MTT assay in each cell
line treated with dasatinib, doxorubicin, or 1:1 combination. B) Viability and proliferation rates after
single and combination treatments. C) Dephosphorylation of phospho‐Src (Tyr416) after single or
combination treatments.
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2.3.4 Combination treatment of dasatinib and doxorubicin synergistically inhibits
metabolism
Small molecule inhibitors are most likely to be used in combination with other
chemotherapeutics to maximize their efficacy. Therefore, we tested the effects of
dasatinib in combination with a doxorubicin, a commonly used chemotherapeutic in
breast cancer to determine whether the two drugs might synergize. Doxorubicin
(Adriamycin ®) is an anthracycline antibiotic that intercalates into DNA, inhibiting
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Table 3: Combination indices demonstrate synergy between dasatinib and doxorubicin in
anti‐proliferation.

replication machinery. I repeated MTT assays using dasatinib alone, doxorubicin alone,
and dasatinib and doxorubicin together (1:1) at three doses (Figure 16a). The metabolic
inhibition of MDA‐MB‐231 cells with doxorubicin was comparable to that seen with
dasatinib treatment at an equivalent dose (IC50 = 160 nM vs. 140 nM). Simultaneous
treatment resulted in a moderate degree of synergism that lowered the IC50 for each drug
to 35 nM. To statistically evaluate the level of cooperating between the two drugs, I use
the CI (combination index), a calculated measure of drug interaction in which values less
than 1 indicate synergy. The CI for combination treatment of dasatinib and doxorubicin
in MDA‐MB‐231 cells was 0.47, indicating moderate synergy. Synergism between
dasatinib and doxorubicin was also seen in treatment of MCF7 and T47D cells.
Interestingly, the degree of synergism was considerably stronger in these cells, which
were only moderately sensitive to dasatinib alone, as compared with the MDA‐MB‐231
cells. The CI values for 50% inhibition of MCF7 and T47D were 0.05 and 0.04, respectively
(Table 3). For MCF7 cells, this degree of synergism lowered the IC50 doses from 12.4 µM
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(dasatinib) and 150 nM (doxorubicin) to just 7.6 nM of each drug. In T47D cells, this
combination lowered the individual doses from 453 nM and 293 nM for dasatinib and
doxorubicin, respectively, to 6.6 nM for each drug when combined. These results
represent a 95% decrease in the dose of doxorubicin required for 50% metabolic
inhibition of MCF7 cells and a 98% decrease in T47D cells. Given the toxic side effects of
doxorubicin, this synergy could have a profound effect on the clinical use of a currently
used chemotherapeutic.
To determine whether the synergistic effects between dasatinib and doxorubicin
could also been seen in the viability or replication rates, I again counted cells using
trypan‐blue exclusion and flow‐cytometric quantification of BrdU uptake (Figure 16b).
Combination treatment in MDA‐MB‐231 cells did not increase the percentage of dead cells
over the rate seen with doxorubicin alone. The combination treatment did, however,
further reduce the rate of BrdU uptake from 5.8% (doxorubicin alone) to 3.9%. In
contrast, MCF7 cells demonstrated no significant reduction in BrdU uptake with
combination treatment, but did exhibit a decrease in viability from 52% (doxorubicin
alone) to 36.4%. Although there was obviously a dramatic effect on proliferation,
combination treatment did not result in any increased effect on the dephosphorylation of
Src (Figure 16c). Whereas I demonstrated that dasatinib treatment of breast cancer cells
results in a G1‐phase arrest, doxorubicin has previously been shown to cause G2/M arrest
in actively growing cells (147). To determine whether the cycle‐arresting effects of one
drug were dominant, I again used flow‐based cell‐cycle analysis of cells treated with
either 100 nM of each drug alone or in combination (Figure 17a). In all three cell lines,
the G2/M arrest characteristic of doxorubicin treatment was the prevalent effect after
combination treatments. After 48 hours of combination treatment, 82.6% of live MDA‐
MB‐231 cells were arrested in G2/M phase, but this was not significantly different than
the arrest seen with doxorubicin alone (82.1% in G2/M). Consistent with G2/M arrest,
accumulation of the CDK inhibitor p21WAF1 was evident after doxorubicin or combination
treatment in all three cell lines (Figure 17b). Only minimal PARP cleavage was evident
after doxorubicin treatment and no increase was seen after combination treatment
(Figure 17b), further confirming my previous results that any cell‐death is occurring
through a non‐apoptotic mechanism.
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Figure 17: Doxorubicin cell cycle arrest dominates dasatinib. A) Cell cycle distribution of
treated cells. B) Cycle arrest through p21 accumulation and lack of apoptosis.
65

A

Figure 18: Dasatinib induces cytoskeletal deregulation in sensitive cells. A) Tubulin and
actin cytoskeleton of sensitive MDA‐MB‐231 cells. B) Tubulin staining of dasatinib‐resistant
MCF7 and T47D cells.

2.3.5 Dasatinibsensitive cells undergo cytoskeletal contraction
MDA‐MB‐231 cells are characterized as basal‐subtype, which also indicates a more
mesenchymal‐like phenotype (148). As such, these cells grow as spindle‐shaped cells with
extensive cell protrusions and are highly migratory and invasive in cell culture. Dasatinib
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treatment was sufficient to disrupt their morphology, resulting in a cell that was still
attached, but severely rounded and contracted (Figure 18a), as demonstrated by
immunofluorescence microscopy of cells probed for tubulin and actin. The morphology of
MCF7 and T47D cells, which are of the luminal subtype and maintain a more epithelial‐
like shape in culture, was not affected by dasatinib treatment (Figure 18b). This is
consistent with the relatively resistant nature of these cells to dasatinib treatment.

B

Figure 19: Effects of dasatinib on cytoskeletal proteins. A) Dephosphorylation of
cytoskeletal‐associated proteins p130, FAK, and CrkL with dasatinib. B) Dephosphorylation
of actin regulator N‐WASp. C) Akt inhibition in sensitive MDA‐MB‐231 cells.

In an effort to differentiate the molecular pathways involved in the variable response to
dasatinib, I probed the cell line panel for the active forms of Src substrates commonly
implicated in cytoskeletal rearrangement. The adaptor protein p130CAS, which is
phosphorylated by Src downstream of integrin activation, was comparably inhibited in all
three cell lines (Figure 19a). Similarly, phosphorylation of FAK at the Src‐targeted
activating site, Tyr576, was comparably inhibited in all three lines. Consistent with this
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was the observation that N‐WASp, a target of both FAK and Src that mediates Cdc42‐
dependent Arp2/3 activation and actin nucleation, was inhibited in all three lines (Figure
19b). It should be noted, however, that MCF7 cells exhibited lower basal phosphorylation
of p130CAS and FAK (Y576) than either the MDA‐MB‐231 or T47D cells. The residual
phosphorylation after 100 nM of dasatinib treatment, however, was equal despite the
starting levels. Of the proteins tested here, only inhibition of CrkL, the Cas‐related kinase,
was variable across the cell lines. Dephosphorylation of CrkL at Tyr207 was strongest in
the MDA‐MB‐231 cells and weakest in the MCF7 cells, a pattern similar to that seen with
the anti‐proliferative effects of dasatinib. Thus, further investigation of CrkL (Tyr207)
phosphorylation may be warranted as a potential marker for dasatinib response in breast
cancer cells.
As opposed to the integrin‐mediated signaling of Src through FAK, Src can also
target the Akt survival pathway through regulation of PI‐3K. Therefore, I probed
dasatinib‐treated cells for phospho‐Akt to determine whether this might contribute to the
effects of dasatinib (Figure 15c). Indeed, MDA‐MB‐231 cells were the only line in which
dasatinib induced the dephosphorylation of Akt at Ser473. As is common in
mesenchymal‐type cells, the MDA‐MB‐231 cells exhibit heightened levels of basal
phospho‐Akt. This suggests that aberrant activation of Akt in basal‐subtype cells may
predispose the cells to the anti‐proliferative effects of dasatinib. It should be noted that
while Akt can be directly inhibited by dasatinib at high concentrations, the dose used in
this experiment (100 nM) is well below the published IC50 for Akt (>50 μM). Thus,
dephosphorylation of Akt may serve as an effective biomarker for the response of breast
cancer cells to dasatinib.
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Figure 20: Dasatinib impairs migration and invasion of MDA‐MB‐231. A) Wound
healing assay after dasatinib pre‐treatment. B) Matrigel‐coated Boyden chamber assay
after dasatinib pre‐treatment.
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2.3.6 Migration and invasion are inhibited by dasatinib treatment
Given the highly dynamic morphology of MDA‐MB‐231 cells and the dasatinib‐
induced inhibition of cytoskeletal proteins (Figure 19), I investigated whether dasatinib
could inhibit cellular migration and invasion of MDA‐MB‐231 cells. To accomplish this, I
quantified wound‐healing (scratch) assays to compare the 2D migration of cells after
pretreatment with dasatinib (Figure 20a). Whereas control‐treated (DMSO) cells were
able to repopulate the denuded area within 16 hours, this migration was significantly
inhibited with both doses (10 nM or 100 nM) of dasatinib (p<0.05). As a measure of 3D
invasion and the ability of cells to degrade and penetrate a Matrigel layer, I used a Boyden
chamber assay (Figure 20b). Treatment with dasatinib greatly reduced (88% reduction
at 50 nM) the number of cells that had successfully invaded to lower chamber (p<0.01).
Because MCF7 and T47D cells are resistant to migration at a wound and are unable to
invade Matrigel, they were not tested in these assays. It should also be noted that, because
of the relatively short time‐point at which these assays were completed, the effects are
not the result of impaired proliferation.
Previous studies have demonstrated the contribution of specialized cytoskeletal
structures known as invadopodia to the penetration of cells through extracellular matrix
(54, 58, 76). These finger‐like projections are bundles of actin, which efficiently degrade
the extracellular matrix via secreted and transmembrane proteinases. In cultured cells,
invadopodia can be visualized grown over a thin layer of FITC‐labeled gelatin. Using this
method, I counted the number of invadopodia formed per cell after dasatinib treatment
(Figure 21a) and found a dramatic decrease (more than 10‐fold) from an average of 5.4
(DMSO‐treated) to 0.4 invadopodia per cell (p<0.05 by t‐test).
Because of the strong anti‐proliferative synergy between dasatinib and
doxorubicin, I also tested the effects of combination treatment on the migration and
invasion of MDA‐MB‐231 cells (Figure 21b). Using the same methods as with individual
treatment, I observed a small decrease in migration (approximately 20%) with
doxorubicin. However, this was significantly improved with combination‐treated cells
(p<0.05). Although the results were not statistically significant, this may even represent a
small improvement on the inhibition seen with dasatinib alone. In the Matrigel‐coated
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Figure 21: Invadopodia and invasion impaired with dasatinib, doxorubicin
combination. A) MDA‐MB‐231 cells grown over FITC‐gelatin. Active invadopodia
within each cell degrade the gelatin (arrows) after overnight incubation. B) Wound
healing‐assay after pretreatment with dasatinib, doxorubicin, or combination. C)
Quantification of Matrigel invasion assay after pretreatment with single or
combination drugs.
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invasion assay, doxorubicin treatment alone resulted in impaired invasion comparable to
dasatinib alone (approximately 90% inhibition). Combination treatment, however,
significantly reduced the number of invading cells to approximately 5% of the untreated
controls (Figure 21c, p<0.05). These data further support the investigation of dasatinib‐
doxorubicin combination treatments to impair the proliferation, migration, and invasion
of breast cancer cells.

2.4 DISCUSSION
c‐Src is commonly overexpressed or hyperactive in human cancers, including
breast cancer. Because of its role at the crossroads of many pathways leading to
proliferation, survival, and migration, downregulation of Src is an attractive therapeutic
target in the treatment of cancer. New small molecule inhibitors like dasatinib (Sprycel®)
target both Src and Abl and are significant because of their relatively high selectivity and
high affinity, making low clinical doses possible. Although dasatinib targets primarily Src
and Abl at low, nanomolar concentrations, it can directly target other tyrosine kinases,
such as Akt, PDGFR, c‐kit, and Ephrin receptor, at higher concentrations. At the
concentrations of dasatinib used in this study, however, it is unlikely that dasatinib is
directly affecting the activity of other tyrosine kinases. Furthermore, I demonstrated that,
in the breast cancer cell lines within this work, there are negligible levels of expression
and/or activation of other potential targets of dasatinib, including c‐kit, EphA2, and Abl.
In these experiments, I investigated the effects of dasatinib on a small panel of
breast cancer cell lines in an attempt to determine the molecular pathways underlying the
variable responsiveness of basal versus luminal subtype cells to dasatinib that had
previously been described (133). Three breast cancer cell lines were tested for their
response to dasatinib in proliferation, inhibition of Src signaling, migration, and invasion.
Furthermore, I investigated the effects of combining dasatinib treatment with doxorubicin
(Adriamycin), a common chemotherapeutic used in breast cancer.
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Initially, I found that the MDA‐MB‐231 cell line, which is triple‐negative (lacking
ER, PR, and HER2) and basal sub‐type, was significantly more sensitive to the anti‐
proliferative effects of dasatinib than the ER‐, PR‐positive, luminal subtype MCF7 and
T47D cell lines. However, Src inhibition, as measured by dephosphorylation of the Tyr416
activation site, was consistent in all three lines. This indicated that Src activation is not a
reliable marker for dasatinib response, despite previous reports in other cell systems
(136, 137). Although some loss of phosphorylation was also evident at the inactivating
site of Src (Tyr527), this occurred at a much higher dose than that required for Tyr416
dephosphorylation and also did not correspond with anti‐proliferative effects of
dasatinib. At high doses, dasatinib may also inhibit other tyrosine kinases like PDGFR and
c‐kit, however these kinases were not present in MDA‐MB‐231 cells. Although the
activation of Abl in MDA‐MB‐231 cells has previously been reported (149), I was unable
to detect any basal phosphorylation of Abl in the breast cancer cell lines tested in these
experiments (data not shown). Interestingly, Gonzalez et al demonstrated decreases in
proliferation of MCF‐7 cells employing dominant‐negative and siRNA‐mediated inhibition
of Src that were not evident with dasatinib‐mediated Src inhibition (40) suggesting that
the non‐pharmacological methods of Src inhibition may have stronger effects than
dasatinib.
Because there was no difference in the inhibition of Src to explain the differences
in anti‐proliferative effects, I screened other potential markers of response. Others have
reported downregulated mRNA levels of caveolin and moesin after dasatinib treatment of
sensitive cells (133, 150). After dasatinib treatment of MDA‐MB‐231 cells, however, I was
unable to detect and change in the protein levels of caveolin or moesin, indicating that
actual protein levels may not be suitable markers of response (data not shown). I did
identify a Src substrate, CrkL, for which dephosphorylation correlated with proliferative
inhibition. CrkL is an adaptor protein that associates with p130CAS and is phosphorylated
at Tyr207 by FAK‐Src complex. This leads to activation of Rac, WAVE/WASp, and Arp2/3
and ultimately actin remodeling. In the dasatinib‐sensitive MDA‐MB‐231 cells, phospho‐
CrkL (Y207) was decreased by 76%, compared with decreases of only 17% and 34% in
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the MCF7 and T47D cells, respectively. This observation warrants further exploration of
CrkL activity as a marker for dasatinib response in breast cancer cells.
Downstream of EGFR, Src activation also modulates activation of the PI‐3K
signaling cascade, leading to activation of the Akt/IKK/NFκB survival pathway (151). The
more mesenchymal‐like MDA‐MB‐231 cells demonstrated high basal levels of Akt
phosphorylation (S473), which was strongly inhibited by 100 nM dasatinib treatment.
Neither basal activity or dasatinib‐dependent inhibition were evident in MCF7 or T47D
cells, suggesting that the phosphorylation status of Akt could be a biomarker to predict or
measure response to dasatinib in breast cancer cells. Kinase assays have demonstrated
that dasatinib is capable of directly inhibiting Akt activity, however the IC50 reported in
kinase assays is much higher (> 50 µM) than the 100 nM doses used in these experiments.
Because several experiments in this study did not indicate any increases in apoptosis, it is
unlikely that dasatinib is affecting cell survival pathways. Rather, Akt‐mediated effects on
the cell cycle regulators Cdk2 and p27Kip1, may explain these results (152‐154).
The vast majority of breast cancer related deaths are the result of metastasis, a
complex process that requires the acquisition a migratory and invasive phenotype by
otherwise non‐motile epithelial cells. Therefore, it is important that therapeutics be
identified that effectively inhibit the migration and invasion of cancer cells. Several Src
substrates, such as FAK, CrkL, and N‐WASp, are intimately involved in adhesion and
reorganization of the cytoskeleton.

Consequently, dasatinib treatment dramatically

altered the morphology of the mesenchymal‐like MDA‐MB‐231 cells in culture. In assays
measuring migration (wound‐healing) and invasion (Matrigel‐coated Boyden chambers),
MDA‐MB‐231 cells were greatly impaired (>90% inhibition) by nano‐molar doses of
dasatinib. The formation of invadopodia, protrusive structures specialized in matrix
degradation, is a critical component of efficient cellular invasion (54, 58, 155). Dasatinib‐
treatment of MDA‐MB‐231 cells significantly decreased formation of invadopodia,
explaining the loss of cellular invasion. However, invasion is a complex process and it
cannot be excluded that other functions that contribute to invasion, such as matrix
metalloprotease activation and secretion, may also be inhibited after dasatinib treatment.
The loss of branched actin structures in dasatinib‐treated cells suggests a loss in actin
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polymerization, the driving force behind cell motility, which may be sufficient to abrogate
any cell migration or invasion.
All of the doses of dasatinib used in this study are below the achievable plasma
concentrations determined in Phase I clinical trials and are therefore clinically relevant
(138). Although small‐molecule inhibitors are potent therapeutics, it is unlikely that they
will be used as single‐drug regimens. Previous studies have demonstrated that
hyperactive Src signaling impaired doxorubicin‐induced senescence (156). Based on this,
I compared the anti‐proliferative effects of dasatinib or doxorubicin alone with
combination treatments and found very strong synergistic effects. Doxorubicin alone
induces cell cycle arrest at the G2/M transition due to inhibition of topoisomerase II.
Based on cell cycle analysis, it was evident that the growth arrest effects of doxorubicin
were dominant in combination treatments. In MCF7 and T47D cells, which are only
moderately responsive to dasatinib alone, the dose of doxorubicin could be reduced by up
to 44‐fold by combining treatment with an equal dose of dasatinib. Therefore, dasatinib
sensitizes cells to the G2/M‐arrest induced by doxorubicin. Vigneron et al suggests a Src‐
dependent blockage of p21WAF1 induction in response to doxorubicin.(40). However, I did
not observe an additive effect on p21 accumulation after combination treatment (data not
shown), indicating that the protective effects of Src are occurring through other
regulators of the G2/M checkpoint. Additionally, combination treatments significantly
reduced the migration and invasion of MDA‐MB‐231 cells beyond the levels achieved with
doxorubicin treatment alone. This suggests that combination treatments might also
impair the metastasis of cancer cells in vitro. All dosing of dasatinib and doxorubicin was
done simultaneously and in equimolar amounts. Adjustments to the dose and schedule of
treatment may affect the observed synergistic effects and should be carefully studied. All
together, these data strongly support the further investigation of multidrug regimens
combining dasatinib with traditional chemotherapeutics such as doxorubicin.
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CHAPTER 3: CIP4 IS REQUIRED FOR MIGRATION AND INVASION OF BREAST CANCER
CELLS
3.1 INTRODUCTION
Metastatic tumors are responsible for the majority of all breast cancer deaths.
Therefore, considerable research is aimed at predicting and preventing invasive behavior
in cancer cells. Metastasis is a complex, multistep process in which cancer cells must
break away from a larger tumor mass, invade the surrounding tissue, enter, survive, and
exit the circulatory system (either lymphatic or blood), and finally survive and proliferate
in a distant organ (157). The initial steps in this cascade require a transition to a motile,
mesenchymal‐like

phenotype.

Many

proteins

involved

in

cell

proliferation,

apoptosis/survival, and motility have been identified with this “invasive signature” (158).
EGFR and several downstream proteins which lead to actin polymerization, including
Cdc42, subunits of the Arp2/3 complex, and cofilin are upregulated in rat models of
mammary carcinoma (158).
EGFR activation directs actin polymerization, targeting the cell towards higher
concentrations of EGF. EGFR signaling, which is potentiated by Src activity, induces
Arp2/3‐dependent dendritic nucleation through a cascade of G‐proteins and
WASP/WAVE family members (33, 158). In the case of lamellipodia, branched actin
networks are nucleated in response activation of Rac and WAVE. Bundled‐actin structures
such as filopodia and invadopodia are dependent on Cdc42 and N‐WASp activation (42,
86, 88).
N‐WASp activation is regulated through auto‐inhibitory folding that is relieved by
its interaction with active Cdc42 and PI(4,5)P2 (159). Phosphorylation of Tyr256 by Src
family kinases, which occurs only in the open conformation, increases N‐WASp activity
(97, 160‐162). A central proline‐rich region adjacent to the Src phosphorylation site
interacts with the SH3 domain of CIP4 (101, 102). CIP4 was originally identified as a
binding partner of both GTP‐Cdc42 and Src family kinases (101, 102).
CIP4 is a member of the F‐BAR family of proteins, with FBP17 and Toca‐1, that
dimerize via alpha‐helical BAR domains into amphipathic, crescent‐shaped structure that
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sense and induce membrane curvature (116, 119).

FBP17 has been implicated in

podosome formation (128) and Toca‐1 potentiates N‐WASp activation and actin
polymerization (105) (97, 163). Recently, Takano et al demonstrated that the increase in
N‐WASp activation and actin polymerization that occurs with FBP17 and Toca‐1 is
dependent on the presence of curved lipid membranes (127).
N‐WASp activity has been reported at invadopodia, specialized membrane
protrusions driven by actin polymerization that promote cellular invasion and
remodeling of the extracellular matrix (54, 58, 71). Expression of N‐WASp and Cdc42 are
both required for invadopodia formation (68). My work demonstrated that Src inhibition
also impairs the formation of invadopodia in human breast cancer cells (Figure 21a).
Although many cytoskeletal proteins have been identified in invadopodia, little attention
has been paid to the role of membrane deforming proteins in the formation of
invadopodia.

3.2 MATERIALS AND METHODS
3.2.1 Cell Culture
Breast cancer cell lines were obtained from the ATCC via the labs of Drs Gordon
Mills and Janet Price (MD Anderson Cancer Center, Houston, TX). All cell lines were
grown at 37OC and 5% CO2 with 10% fetal calf serum (Hyclone, Logan, UT), 100 U/ml
penicillin, and 100 mg/ml streptomycin. MDA‐MB‐231 and T47D cells were grown in
DMEM/F12 media (Invitrogen, Carlsbad, CA). MCF7 cells were maintained in MEM media
(Invitrogen) supplemented with 10% fetal calf serum, 2mM L‐glutamine, 0.1mM non‐
essential amino acids, 1mM sodium pyruvate, and MEM vitamin solution. All other cell
lines were maintained in DMEM with 4500 mg/L glucose and 10% fetal calf serum
3.2.2 siRNAmediated knockdown of CIP4 and NWASp expression
MDA‐MB‐231 cells were transiently transfected with 10 nM of CIP4 or N‐WASp‐
directed or non‐targeting siRNA (Qiagen) using the HiPerFect transfection reagent
(Qiagen). Decreases in protein expression were verified by western blotting of whole cell
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lysates, as described in Section 2.2.4. After 72 hours, cells were replated for the
appropriate functional assay.
3.2.2 Immunofluorescence and Invadopodia imaging
Cells were grown on glass coverslips, fixed in 3.7% formaldehyde (30 minutes),
permeabilized with 0.1% TritonX‐100 (5 minutes), and blocked in 1% BSA (30 minutes),
each at room temperature.

Samples were incubated with mouse α‐CIP4 antibody

overnight at 4o C, followed by Cy3‐ or Cy5‐conjugated anti‐mouse and TRITC‐phalloidin
for 1 hour at room temperature. Cells were re‐fixed in 3.7% formaldehyde. Slides were
prepared using ProLong Antifade with DAPI mounting media (Molecular Probes), and
imaged with either a Nikon Eclipse TE2000U microscope with MetaMorph imaging
software (Molecular Devices, Sunnyvale, CA) or Nikon A1 Confocal Microscope with Nikon
NIS‐Elements software (Melville, NY).
Gelatin was labeled with FITC (Sigma) in 0.1 M bicarbonate buffer (pH 9.0),
dialyzed extensively against PBS, and stored at 4o C. FITC‐gelatin was crosslinked with
0.5% glutaraldehyde (10 minutes on ice and 30 minutes at room temperature) and
reduced with 1 mg/mL sodium borohydride (5 minutes at room temperature). Cells were
plated on FITC‐gelatin‐coated dishes in complete media and allowed to invade for 16‐20
hours, then processed as described above. Samples were stained with TRITC‐phalloidin.
Invadopodia were counted from 6 to 10 random fields in each sample and averaged over
multiple experiments. Gelatin degradation was quantified using the Macnification
software (Orbicule BVBA, Heverlee, Belgium).
3.2.3 Migration and Invasion Assays
Migration was measured by wound healing assay, in which cells were grown to
80% confluence in 6‐well plates and streaked with a sterile pipet tip to create a wound.
The wound width was measured at marked locations immediately after wounding and
again after 24 hours of recovery time. Measurements were taken at mutiple points along
the length of the wound to create an average for each individual wound, and samples
were tested in triplicate. Invasion assays were performed using Matrigel invasion
chambers (BD Biosciences, Bedford, MA) seeded with 2.5 x 104 cells per well. Complete
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media was used in both the upper and lower chambers, with or without 100 ng/mL EGF
added only to the lower chamber. Cells were allowed to invade for 24 hours through the
Matrigel and 8 mm‐pore membrane, at which point the inserts were removed, the upper
side of the membranes were scrubbed. The cells were then fixed in methanol, rinsed in
distilled water (1 minute each), air‐dried, and mounted on slides with ProLong Antifade
with DAPI (Molecular Probes). Membranes were visualized with Zeiss epifluorescence
microscope to count the number of invading cells in 9 random fields per sample. Samples
from multiple experiment were averaged.
3.2.4 Acceptorphotobleaching FRET
Acceptor photobleaching FRET (apFRET) was used to quantify the EGF‐dependent
interactions between CIP4/N‐WASp. All images were recorded using a Zeiss LSM 510
confocal microscope using a 63X, 1.3 NA objective. apFRET was applied largely as
described previously where bleach settings are defined empirically (164, 165). Briefly, a
cell expressing YFP‐CIP4 and CFP‐N‐WASp was selected and 3 regions of interest (ROIs)
were drawn for YFP bleaching and controls. The large ROI (ROI 3) was scanned 10 times
using routine scanning settings. The bleach ROIs (ROI1) region was then bleached at
100% intensity for 1000 iterations or approximately 3 min. One ROI (ROI 2) was drawn
to measure any potential for off‐target bleaching, which accounted for less than 1% of
changes in YFP and CFP. Following the bleach, 10 more scans were taken using the
prebleach settings.

The FRET efficiency (increase in CFP upon YFP bleaching) was

calculated using the following equation:

Furthermore, the distance between fluorophores was calculated by solving the
equation for r:
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Control experiments were performed to validate the apFRET protocol. These
included vector controls (CFP, YFP) co‐transfected with either YFP‐CIP4 or CFP‐N‐WASp,
respectively. In these control experiments, the false positive increase in CFP or CFP‐N‐
WASp upon bleaching YFP‐CIP4 or YFP, respectively, ranged from 1‐6%.

Table 4: Comparison of invasive behaviors in breast cancer cell lines

3.3 RESULTS
3.3.1 Invasive breast cancer cell lines express high levels of CIP4
To determine whether CIP4 expression levels correlated with invasiveness, I
compiled a panel of breast cancer cell lines of varying invasiveness. Based on previous
studies, MDA‐MB‐231 and Hs578T cells are highly invasive in in vitro Boyden chamber
assays (1) and also invade and metastasize in nude mice (Table 4) (66). In contrast,
MCF7, T47D, and SKBR3 cells are weakly or non‐invasive in vitro (1). These two groups
correspond with basal (MDA‐MB‐231 and Hs578T) and luminal (MCF7, T47D, and
SKBR3) subtypes (1). Through immunoblotting, I found that CIP4 protein expression was
elevated in the invasive lines as compared with the weakly‐ or non‐invasive lines (Figure
23a). This trend was not seen with FBP17 or Toca‐1 (Figure 22a). This difference was
statistically significant (p<0.05) based on densitometric quantification (Figure 22b).
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Figure 22: Overexpression of CIP4 in invasive breast cancer cell lines. A) Western blot of
CIP4, FBP17, and Toca‐1 in breast cancer cell line panel. B) Quantification based on
densitometric analysis of western blot of CIP4. C) Quantitative PCR of CIP4, Toca1, and
FBP17 mRNA.

Expression of CIP4 was also upregulated at the mRNA level in the MDA‐MB‐231 cells
(Figure 22c), whereas this pattern was not evident with FBP17 or Toca‐1. The average
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CIP4 mRNA level was 6.3‐fold higher in MDA‐MB‐231 cells compared with MCF‐7
(p=0.009) and 2.8‐fold higher versus T47D (p=0.026).
Our work in the Corey lab and others have identified multiple isoforms of CIP4 that
lack functional SH3 domains due to retained intronic sequences (102, 109). Because this
structure could have a profound impact on the function of CIP4, I used PCR amplification and
digestion to determine whether any of these alternative isoforms were present in the breast
cancer cell lines. I screened MDA-MB-231, MCF7, and T47D cell lines for the five CIP4
isoforms (Figure 8b), and found that only CIP4a, the ubiquitously expressed, full-length
protein, was expressed (data not shown). Therefore, all discussion of CIP4 here refers to the
CIP4a isoform.

Figure 23: Upregulation of CIP4 mRNA in triple‐negative cell lines. Gene analysis of 51 well
characterized breast cancer cell lines, comparing triple‐negative (Group 1) to other breast
cancer cell lines (Group 2). From Neve (2006) and analyzed by Oncomine. (1)

MDA‐MB‐231 and Hs578t cell lines lack ER, PR, HER2, a phenotype known as
“triple‐negative” that is clinically relevant due to increased invasion, growth rate, and
resistance to targeted therapies (166). To determine whether increased CIP4 expression
was present in a larger set of triple‐negative breast cancer cell lines, bioinformatic
analysis of 51 well‐characterized lines (1) was screened for CIP4 (Figure 23). CIP4 mRNA
was significantly increased in the triple‐negative group as compared with cell lines of
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other biomarker status (p=1.03x10‐7, t‐test). Again, no significant difference was seen in
the expression of FBP17 or Toca‐1 (Figure 23).
Because of the membrane‐binding properties conferred by the F‐BAR domain, subcellular
localization may affect its function. I compared the localization of endogenous CIP4 in
MDA‐MB‐231 cells with MCF7 and MCF10a (non‐cancerous mammary cell line) and found
that CIP4 was enriched at the plasma membrane in only the invasive MDA‐MB‐231 cell
line (Figure 24, arrows). MCF7 and MCF10a had little CIP4 at the plasma membrane.

Figure 24: Subcellular localization of endogenous CIP4. Staining of unstimulated MDA‐
MB‐231, MCF7, MCF10a.

3.3.2 CIP4 promotes cellular migration in MDAMB231 cells
To investigate whether CIP4 expression correlated with cellular motility in MDA‐
MB‐231 cells, I examined it localization in actively migrating cells. It appears that
endogenous CIP4 localizes to the lamellipodia in migrating cells (Figure 25a, arrows),
suggesting a role in cell migration. Therefore, I used siRNA to specifically downregulate
CIP4 (Figure 25b) and tested 2D migration with a wound‐healing (scratch) assay. After
24 hours recovery, CIP4‐depleted cells had repopulated significantly less of the denuded
area compared with control cells (Figure 25c). Quantification indicated that the residual
wounds in CIP4‐knockdown cells were more than twice the width of the control wounds
(p<0.001). To exclude the possibility that this effect was an artifact of proliferative
changes in CIP4‐depeleted cells, I also conducted MTT assays at 24, 48, and 72 hours after
knockdown (Figure 25d) and found no differences between control CIP4‐knockdown
cells. These data indicate that CIP4 is required for cellular migration.
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Figure 25: Depletion of CIP4 impairs migration, not proliferation. A) Endogenous CIP4
in actively migrating MDAMB‐231 cell (solid arrows). Dashed arrow indicates direction
of movement. B) Knockdown of CIP4 protein 48 and 72 hours after siRNA transfection.
C) Wound‐healing assay at 0 and 24 hour after wound in CIP4‐depleted cells.
Quantification based on average width of wound before and after recovery. D) MTT
assay after siRNA transfection.
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3.3.3 CIP4 controls NWASp activation in response to EGF
EGF stimulation activates N‐WASp via Cdc42 (91, 167). Given that CIP4 interacts
with Cdc42 (101) and localizes with EGFR‐containing vesicles (168), I speculated that
CIP4 might interact with N‐WASp in an EGF‐dependent manner. Initially, co‐
immunoprecipitation experiments indicated that EGF transiently increased CIP4‐N‐WASp
interaction at around 1 minute after treatment (data not shown). To confirm this effect
and investigate the kinetics more precisely, we used acceptor photobleaching FRET
microscopy to quantify the energy transfer between YFP‐CIP4 and CFP‐N‐WASp in MDA‐
MB‐231 cells. Indeed, EGF treatment produced a spike in interaction at around 10
seconds (Figure 26a).
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Figure 26: CIP4 interacts and increases activation of N‐WASp downstream of EGFR. A)
Quantification of apFRET experiments demonstrating increase in interaction between YFP‐
CIP4 and CFP‐N‐WASp in MDA‐MB‐231 cells after EGF treatment. B) Western blot for
phospho‐N‐WASp (Y256) (arrow) in cells after siRNA transfection. Quantification based on
densitometric analysis.
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Figure 27: CIP4 enriched at invadopodia of MDA‐MB‐231 cells on gelatin. A) Staining of
CIP4 and actin in cells grown on FITC‐labeled gelatin reveals active invadopodia (arrows). B)
Z‐stack projections demonstrate CIP4 at base of invadopodia.
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The Src‐targeted Tyr256 of N‐WASp is only accessible in the open conformation
and is associated with increased activity (97, 160‐162). Therefore, I used the
phosphorylation status of Tyr256 as a surrogate marker for N‐WASp activity downstream
of EGFR activation. In control cells, stimulation of EGFR increased N‐WASp
phosphorylation (Figure 26b). To determine whether the expression level of CIP4
affected N‐WASp activation, I immunoblotted for phospho‐N‐WASp in control and CIP4‐
depleted cells treated with EGF. This demonstrated that CIP4 is required N‐WASp
phosphorylation in resting and EGF‐stimulated cells, suggesting that CIP4 promotes the
activation of N‐WASp.
3.3.4 CIP4 is required for optimal invadopodia formation
Previous studies have demonstrated that N‐WASp and Cdc42 are required for
invadopodia formation (68, 71, 74). Because CIP4 regulates the activation of N‐WASp and
interacts with active Cdc42, it may also participate in invadopodia formation. To visualize
invadopodia in cultured cells, MDA‐MB‐231 cells were grown over a thin layer of FITC‐
gelatin overnight. Active invadopodia were evident as dots of strong actin staining that
co‐localized with areas of degraded gelatin substrate (Figure 27a, arrows) (58, 71, 155).
I found that endogenous CIP4 was also enriched at the invadopodia structures. Z‐stack
projections of the invadopodia demonstrated that CIP4 was specifically located at the
base of the invadopodia, whereas actin was present throughout the length of the structure
(Figure 27b).
To determine whether CIP4 is also required for invadopodia formation, I used the
FITC‐gelatin assay to quantify invadopodia in MDA‐MB‐231 cells after CIP4 depletion. In
comparing the percentage of cells that were positive for invadopodia, there was no
significant difference (Figure 29a). However, there was a significant difference in the
number of invadopodia formed by each cell (Figure 28c, p<0.05) that was comparable to
the defect seen with N‐WASp depletion (Figure 28b). Furthermore, the average area of
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gelatin degradation per cell was significantly decreased by CIP4 knockdown (Figure 28d,
p<0.001). Again, this effect was comparable to that seen with N‐WASp knockdown.

C

D

Figure 28: CIP4 required for formation and function of invadopodia. A) Quantification of
invadopodia by scoring cells as with or without invadopodia. B) Western blot of N‐WASp
knockdown by siRNA. C) Quantification of invadopodia formation after siRNA knockdown
by average number of invadopodia formed per cell. D) Average area of gelatin degradation,
normalized to cell number, after siRNA transfection.
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3.3.5 CIP4 promotes invasion of MDAMB231 cells in vitro
Because invadopodia formation correlates with cellular invasion, I continued the
study of CIP4 knockdown in MDA‐MB‐231 cells to Boyden chamber assays. After 72 hours
of CIP4‐siRNA treatment, cells were transferred to Matrigel‐coated chambers and allowed
to invade for an additional 24 hours. CIP4‐depletion by two‐independent siRNA
sequences demonstrated that CIP4 loss significantly inhibited invasion (Figure 30a,
p<0.01) as compared with control cells. This represents a decrease in invasion of
approximately 76%, which is similar to the degree of inhibition with N‐WASp‐siRNA or
Src‐inhibition (Figure 20b).
Although MDA‐MB‐231 cells invade through Matrigel spontaneously, the presence
of EGF in the lower chamber can increase their rate of invasion (Figure 30b). This
responsiveness

to

EGF

was

completely
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abrogated

by

CIP4‐depletion.

A

Figure 29: CIP4 required for basal and EGF‐dependent invasion. A) Matrigel‐coated Boyden
chamber assay with MDA‐MB‐231 cells after siRNA transfection. Representative images of
each sample after invasion. B) Invasion assay with EGF‐spiked media in lower chamber.
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3.4 DISCUSSION
Several CIP4‐associated proteins such as Cdc42, N‐WASp, and Src are well
established as regulators of cellular invasion and invadopodia formation in cancer cells.
However, a role for CIP4 and the F‐BAR family of proteins in cancer cell motility has not
been previously investigated. In this set of experiments, I demonstrated that CIP4
expression is upregulated at both the protein and mRNA levels in invasive breast cancer
cells, suggesting that CIP4 could be a predictive marker for invasion. CIP4 expression also
correlated with the clinically significant “triple‐negative” cell line. Therefore, CIP4 could
be included as a protein in the “invasive signature” as a prognostic marker.
In resting cells, I demonstrated that endogenous CIP4 was concentrated at the
plasma membrane of cells with high CIP4 expression, indicating that subcellular
localization of CIP4 may have a significant role in its function. Using the highly invasive,
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triple‐negative breast cancer cell line MDA‐MB‐231 as a model, I found that siRNA‐
mediated depletion of CIP4 impaired the 2D migration of cells in wound‐healing assays.
This reinforces the notion that CIP4 regulates the actin cytoskeleton. While Cdc42 and N‐
WASp are not typically implicated in lamellipodia formation, they are both required for
the formation of the direction‐sensing filopodia at the leading edge of the cell. Loss of
CIP4 may impair mechanisms of filopodia formation, therefore disrupting directional cell
migration.
N‐WASp serves as a major effector for the Rho GTPase Cdc42, mediating Cdc42‐
dependent Arp2/3 activation and actin polymerization (47, 94, 98, 159, 169). Previously,
Ho et al demonstrated that TOCA‐1, a related F‐BAR protein, strengthens the Cdc42‐
mediated activation of N‐WASp, resulting in increased actin polymerization in
fluorescence‐based, cell‐free assays (105). Using liposomes, Takano et al demonstrated
that FBP17 and Toca‐1 increased N‐WASp‐mediated actin polymerization through a
membrane‐curvature dependent mechanism. I hypothesized that CIP4 may function
through a similar mechanism, stabilizing the activation of N‐WASp. Because N‐WASp
activation at the plasma membrane is increased downstream of EGF (71), I investigated
whether the interaction between CIP4 and N‐WASp might also be responsive to EGF
stimulation.
Through co‐immunoprecipitation and apFRET microscopy, I demonstrated that
the interaction between CIP4 and N‐WASp is rapidly and transiently increased after EGFR
activation. The peak in interaction was seen at approximately 10 seconds after
stimulation and lingers for approximately one minute. This time‐frame corresponds with
the activation of a FRET‐based N‐WASp biosensor, as demonstrated by Lorenz et al (71).
Activation of N‐WASp is regulated through auto‐inhibitory folding, which precludes
phosphorylation of Tyr256 by Src/FAK (97, 162, 170). In the absence of CIP4, basal
phosphorylation of Tyr256 was decreased and EGF‐induced phosphorylation was
abrogated. While not a direct measure of N‐WASp activation, phospho‐Tyr256 has been
correlated with activation and actin polymerization (97, 162, 170). This suggests that
CIP4 expression is required for N‐WASp activation.
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The EGFR‐Cdc42‐N‐WASp signaling pathway has been implicated in the formation
of invadopodia, actin‐based protrusions that are specialized in matrix degradation (68,
74, 91). Since CIP4 may participate in this cascade, I examined the invadopodia formed by
MDA‐MB‐231 cells in culture through immunofluorescence microscopy. Along with actin,
CIP4 was enriched at active invadopodia. CIP4‐depletion decreased both the number of
invadopodia formed and the area of gelatin‐degradation per cell, indicating that CIP4 is
critical to the formation and function of invadopodia. No F‐BAR family members have
been previously associated with invadopodia of cancer cells. Through ELISA assays, I was
able to detect a small decrease in the secretion of MMP‐9, a gelatin‐specific
metalloprotease that is relevant in invadopodia. However, the 20% inhibition in MMP‐9 is
unlikely to account for the approximately 75% decrease in invadopodia formation. The
loss of invadopodia and gelatin degradation associated with CIP4 knockdown was
comparable to that seen with depletion of N‐WASp, which is well established as a critical
component of invadopodia formation.
Invadopodia are important to cellular invasion, so I examined whether the loss of
CIP4 would affect the invasiveness of MDA‐MB‐231 cells in vitro. I found that loss of CIP4
dramatically inhibited invasion through a Matrigel layer and abrogated the
chemoinvasive behavior towards EGF. This supports the hypothesis that CIP4 promotes
invasion through the Cdc42‐N‐WASp signaling pathways.
CIP4’s structure suggests that it functions as a scaffolding protein to promote actin
polymerization at areas membrane curvature by integrating N‐WASp regulation with F‐
BAR mediated membrane curvature. Through upregulation of this mechanism, CIP4
overexpression may contribute to the invasive phenotype of triple‐negative, EGFR‐
positive breast cancers. These results support the further investigation of CIP4 as a
potential biomarker for invasive breast cancers.
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CHAPTER 4: GENERAL SUMMARY
Invasion is a phenotypic hallmark of cancer that can lead to metastasis, which is
associated with a poor prognosis (9, 157). Five‐year survival rates decrease sharply with
diagnosis of advanced breast cancer (23.3%) compared with localized disease (98.3%)
(2). One subtype of breast cancer that is associated with aggressive disease and increased
metastasis is the “triple‐negative” tumors, frequently of the basal subtype. These cancers
are refractory to current anti‐HER2 targeted therapy (166, 171) and frequently
overexpress the EGF receptor (EGFR), which also correlates with invasiveness and poor
prognosis (172). Therefore, anti‐invasion therapies could have a significant impact on the
treatment of advanced breast cancers. Several proteins have been associated with the
invasive phenotype, many of which are linked to the cytoskeletal system, including Src,
Cdc42, N‐WASp (31, 63, 173).
My experiments address the role of the tyrosine kinase Src and the F‐BAR protein
CIP4 in promoting the migration and invasion of breast cancer cells in vitro. Increased
expression and activity of Src is common in human breast cancers and is frequently co‐
expressed with elevated EGFR. I demonstrated that inhibition of Src through dasatinib, a
small molecule inhibitor of Src and Abl, impairs not only the proliferation of human breast
cancer cells, but also their migration and invasion in in vitro assays (173). Although
dasatinib has been approved for the treatment of imatinib‐resistant leukemias, clinical
testing of dasatinib in solid tumors is still ongoing. Combination therapies that include
dasatinib have not previously been studied in breast cancer. My data presents a novel
finding that dasatinib and the anthracycline doxorubicin synergistically inhibit cell
proliferation, representing a significant decrease (greater than 40‐fold) in the dose of
doxorubicin required for 50% inhibition of cell proliferation. Because Src is involved in a
wide variety of signaling pathways, the exact mechanism of this synergy is still unknown.
In my research, I was unable to identify cooperative inhibition of any single pathway as a
result of combination treatments. This may suggest that the synergistic inhibition of
proliferation is the result of blockages in independent pathways. Src inhibition also
significantly impairs cell migration and invasion of the clinically significant “triple‐
negative” breast cancer cells, which are associated with a higher rate of metastasis. My
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data suggests that this inhibition occurs through downstream inhibition of the
cytoskeletal regulators N‐WASp and FAK.
Another Src‐associated protein is the F‐BAR protein CIP4, which also interacts
with N‐WASp. My preliminary work demonstrated that CIP4 is upregulated in invasive
breast cancer cells, leading me to investigate its contribution to cytoskeletal
reorganization. Analysis of CIP4 mRNA expression in a larger set breast cancer cell lines
confirmed that CIP4 was elevated in “triple‐negative” cell lines, which are typically more
invasive. To correlate CIP4 expression with invasiveness in patient samples, I attempted
to stain tissue samples with anti‐CIP4 antibodies. However, immunohistochemical
staining for CIP4 (with multiple commercially available and homemade antibodies) was
never successful, possibly due to poor retrieval of CIP4 antigen or degradation of CIP4
before the fixation process. Because of this lack of reliable IHC staining, the development
of CIP4 as a biomarker of invasion is limited.
CIP4 is considered a scaffolding protein that recruits N‐WASp and dynamin to
areas of membrane curvature. My results demonstrate that CIP4 also regulates the
activation of N‐WASp downstream of EGFR activation. I have also shown that CIP4
depletion significantly impairs the migration and invasion of breast cancer cells in vitro.
Takano et al described a model in which the static repulsion between acidic residues near
the SH3 domain of FBP17/Toca‐1 and the hydrophobic plasma membrane forces the SH3
domain away from the membrane where it binds N‐WASp and stabilizes its binding to the
membrane (127). Building on this model, I propose that a similar arrangement is present
in CIP4 dimers bound to the plasma membrane. As static repulsion pushes the SH3
domain away from the plasma membrane and the hydrophobic outer face of the F‐BAR
domains, CIP4 acts as a stabilizer for the open conformation of N‐WASp (Figure 10). N‐
WASp binds the plasma membrane directly through its basic region, tethering one end of
the protein to PI(4,5)P2‐enriched membranes. The interaction with CIP4 serves two
functions: Firstly, binding to CIP4 localizes N‐WASp to areas of membrane curvature such
as budding vesicles or invadopodia. Secondly, the spring‐like action of CIP4 holds N‐WASp
in an open conformation, potentiating its activation by increasing access to the Src/FAK‐
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targeted phosphorylation site (Tyr256) and the Cdc42 (GTPase)‐binding domain. GTP‐
Cdc42 and Src phosphorylation are both associated with increased actin polymerization
via N‐WASp(96, 97, 159). Our lab initially identified CIP4 as a novel binding partner of
SFKs and has demonstrated Src‐dependent phosphorylation (unpublished results)
adjacent to the acidic region described by Takano et al. Therefore, I propose that
phosphorylation of CIP4 by Src increases the hydrophobic nature of this region and
increases the electrostatic repulsion holding CIP4’s SH3 domain away from the
membrane. Essentially, this stiffens the spring action of CIP4 at the plasma membrane and
further strengthens the stabilization of open N‐WASp.
F‐BAR proteins have not previously been identified at invadopodia. My data
demonstrate the novel finding that CIP4 is localized to invadopodia of breast cancer cells
in vitro. I also show that depletion of CIP4 significantly impairs the formation and function
(gelatin‐degradation) of invadopodia. Furthermore, this loss of invadopodia translates to
a loss in invasiveness through Matrigel‐coated Boyden chambers. Together, these data
suggest that CIP4 is a critical component of the invasive phenotype. Therefore, the
overexpression of CIP4, as seen in triple‐negative human breast cancer cell lines, may
serve as a predictive marker for invasive disease and potential therapeutic target.
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Figure 30: Proposed model for the scaffolding role for CIP4 promoting N‐WASp activation at invadopodia.
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CHAPTER 5: FUTURE DIRECTIONS
My experiments with dasatinib inhibition of Src demonstrated a high degree of
synergy with doxorubicin in impairing cell proliferation. However, the mechanism
underlying this phenomenon is still unclear. Future research into combination therapies
including both dasatinib and doxorubicin should focus on the molecular pathways that
account for the Src‐dependent resistance to doxorubicin in breast cancer cells.
Although research in our lab identified a Src phosphorylation site within CIP4, the
effects of this modification are unknown. I have postulated that this phosphate group
increases the electrostatic repulsion that forces the SH3 domain away from the plasma
membrane, stiffening the spring‐like mechanism by which CIP4 stabilizes the open
conformation of N‐WASp. A major drawback in the study of CIP4 is the current lack of any
measure of CIP4 function. Similar to the FRET‐based studies described by Takano et al,
the structural arrangement of membrane‐bound CIP4 and N‐WASp could be studied in
response to Src phosphorylation and the availability of curved membranes. Disruption of
the phosphorylation by Src, which could be accomplished with dasatinib treatment, may
weaken the spring‐action of CIP4 and impair its ability to stabilize the open N‐WASp
conformation. Cell‐free actin polymerization assays may provide a quantifiable method
for measuring CIP4 function. Src inhibition through dasatinib could be used to study the
effects on CIP4 through these assays. Furthermore, the Src binding region of CIP4 may
also allow it to act as a scaffold to directly promote N‐WASp phosphorylation by Src at the
plasma membrane. The establishment of CIP4 as a downstream effector of Src would
represent a novel pathway in the Src‐signaling cascade. These experiments could initially
be carried out using cell‐free, liposome based assays but would be more relevant when
performed in invadopodia model systems. Because F‐BAR interaction with the plasma
membrane is curvature‐dependent, cells grown on standard culture surfaces may not be
the optimal models. Rather, cells grown on gelatin, allowing formation of invadopodia
may provide more sites for formation of these complexes. Furthermore, efficient
activation of integrins by the presence of extracellular matrix may also encourage these
complexes.
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Mutants of CIP4 that lack functional binding sites for N‐WASp or Cdc42 or which
carry point mutations in the Src‐phosphorylation site would be useful tools in elucidating
which interactions are critical the function of CIP4. Biochemical experiments are needed
to determine whether CIP4 is required for N‐WASp interaction with Cdc42. Because CIP4
overexpression correlates with invasiveness, biochemical studies should be performed to
determine the effects of saturating concentrations of CIP4 in comparison to N‐WASp and
Cdc42. The SH3 domain of CIP4 also interacts with dynamin, an important component of
vesicle fission. Dynamin is also found in invadopodia, although its function there is
unknown. More research is needed to determine whether CIP4 is required for
recruitment of dynamin to invadopodia or in some way contributes to its function.
My results clearly demonstrated increased CIP4 expression, at the mRNA and
protein levels, in invasive and “triple‐negative” breast cancer cell lines. However, the
regulation of CIP4 expression has not previously been examined. Because “triple‐
negative” cell lines frequently express high levels of EGFR, it is possible that transcription
factors activated downstream of EGFR are responsible for CIP4 expression.
The time‐line of invadopodia formation is not well understood, therefore the stage
at which CIP4 and N‐WASp are recruited to invadopodia is unknown. Live‐cell time‐lapse
microscopy, using fluorescently tagged CIP4 and N‐WASp would demonstrate whether
CIP4 is required for the early formation of invadopodia or the maintenance of a more
stable structure. If CIP4 is required for laying the initial base of branched actin,
invadopodia formation will be impaired at a very early stage of development. Breast
cancer cells that stably express fluorescently labeled actin monomers would be very
useful for this assay.
I demonstrated that CIP4‐depletion severely impairs the cellular invasion of breast
cancer cells in vitro, however this should be transferred to animal models to determine
whether inhibition of CIP4 leads to an inhibition in metastasis. Because the experiments
here represent localized invasion, the most germane experiments would focus on local
tissue invasion of orthotopic tumors in nude mice, as evaluated by histological studies.
Our work in the Corey lab has produced CIP4‐null transgenic mice (174), which have a
minimal phenotype of rapid clearance of blood glucose resulting from delayed
endocytosis of the GLUT4 glucose transporter. Although the mice do not suffer any
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obvious defects in normal cell migration in development, it is possible that loss of CIP4
may play a more specific role in the invasive process of transformed epithelial cells.
Therefore, cross‐breeding of the CIP4‐null mice with mouse models of metastasis, such as
the MMTV model, would be useful to determine the contribution of CIP4 to invasion and
metastasis of spontaneously generated tumors in vivo. Such a system would also be useful
in determining the importance of CIP4 in Src‐dependent pathways, using dasatinib as an
anti‐metastatic agent. Because of the minimal phenotype of the CIP4‐null mice and the
close homology of CIP4 to FBP17 and Toca‐1, the generation of triple‐knockout mouse
could produce a stronger effect on development or other normal migratory processes.
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